UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K/A

(Amendment No. 1)







|x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ------------------------------------------------------------------------------------

For the fiscal year ended December 31, 2007

OR



| ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ----------------------------------------------------------------------------------------

For the transition period
from                    to

Commission File Number 000-23541

NANOGEN, INC.

(Exact name of Registrant as specified in its charter)



|                                                               |  |                                     
|-------------------------------------------------------------- |  | ------------------------------------
|Delaware                                                       |  | 33-0489621                          
|(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)
|                                                               | 
|10398 Pacific Center Court, San Diego, CA                      |  | 92121                               
|(Address of principal executive offices)                       |  | (Zip code)                          

Registrants telephone number, including area code: (858) 410-4600

Securities registered pursuant to Section 12(b) of the Act:



|                                |  |                                     
|------------------------------- |  | ------------------------------------
|Title of Class                  |  | Name of Exchange on Which Registered
|Common Stock $0.001 par value   |  | NASDAQ Global Market, Inc.          
|Preferred Stock Purchase Rights |  |                                     

Securities registered pursuant to Section 12(g) of the Act:

NONE

Indicate by check mark if the registrant
is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes  ̈ No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or
Section 15(d) of the Act. Yes  ̈ No x

Indicate by
check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES    x            NO     ̈

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of
registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.    x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of
accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one):



|                             |  |                        |  |                           
|---------------------------- |  | ---------------------- |  | --------------------------
|Large accelerated filer     ̈ |  | Accelerated filer    x |  | Non-accelerated filer     ̈

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of
the Exchange Act).

YES     ̈            NO    x

The aggregate market value of the voting stock held by non-affiliates of the registrant based upon the closing sale price of the common stock on June 30, 2007 (the last day of the registrants most recently
completed second fiscal quarter), as reported on the Nasdaq Global Market was approximately $92,888,653. For purposes hereof, directors, executive officers and 10% or greater shareholders have been deemed affiliates. This determination of affiliate
status is not necessarily a conclusive determination for other purposes.

The number of shares outstanding of the registrants common
stock was 73,403,135 as of April 7, 2008.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrants Annual Report on Form 10-K for the fiscal year ended December 31, 2007 filed with the Securities and Exchange
Commission, or the SEC, on March 31, 2008 are incorporated by reference into Part III of this Annual Report on Form 10-K.









---

EXPLANATORY NOTE

This Amendment No. 1 on Form 10-K/A (this Amendment) amends the Registrants Annual Report on Form 10-K for the fiscal year ended December 31, 2007, originally filed on March 31, 2008
(the Original Filing). The Registrant is refiling Part III to include the information required by Items 10, 11, 12, 13 and 14 of Part III within the period required by General Instruction G(3) to Form 10-K. In addition, in connection
with the filing of this Amendment and pursuant to the rules of the SEC, the Registrant is including with this Amendment certain currently dated certifications. Except as described above, no other changes have been made to the Original Filing.



---

PART III



|Item 10. | Directors, Executive Officers and Corporate Governance
|-------- | ------------------------------------------------------

Executive Officers of the Company

The names of and certain biographical information of our current executive officers are
as follows:



|                   |  |     |  |                                                  
|------------------ |  | --- |  | -------------------------------------------------
|Name               |  | Age |  | Position                                         
|Howard C. Birndorf |  | 58  |  | Chairman and Chief Executive Officer             
|David Ludvigson    |  | 57  |  | President and Chief Operating Officer            
|Nicholas J. Venuto |  | 38  |  | Chief Financial Officer                          
|Graham Lidgard     |  | 60  |  | Senior Vice President, Research and Development  
|William L. Respess |  | 69  |  | Senior Vice President, General Counsel, Secretary

Howard C. Birndorf. Mr. Birndorf, a founder of Nanogen, has served as our Chairman of
the Board since October 1993. From 1993 to April 2001 he served as Chief Executive Officer, from April 2001 to December 2002 he served as Executive Chairman, and since December 2002 he has served as Chief Executive Officer. Mr. Birndorf also
served as our President, from January 2000 to September 2000, and as Chief Financial Officer, from December 1997 to July 1998 and from September 1993 to October 1997. Mr. Birndorf was a co-founder and Chairman Emeritus of Ligand Pharmaceutical
Incorporated, where from January 1988 to November 1991 he was President and Chief Executive Officer. He was also a co-founder, director and Executive Vice President of Gen-Probe Incorporated, co-founder and Vice President of Corporate Development at
Hybritech Incorporated, co-founder and director of IDEC Pharmaceuticals Corporation, and was involved in the formation of Gensia Pharmaceuticals, Inc. (currently known as SICOR Inc.) where he was a director. From November 1991 to January 1993,
Mr. Birndorf was President of Birndorf Technology Development, an investment and consulting company, and a founding director of Neurocrine Biosciences, Inc. He is a founding investor of Kiyon, Inc., chairman of the board of FasTraQ, Inc. and HA
Cell Technology, and serves on the advisory board of Scripps Clinic-Green Hospital. In addition, Mr. Birndorf is currently a member of the Board of Directors of Jurilab, Ltd. He received the Life Sciences Legend award at bioFusion 2002.
Mr. Birndorf received a B.A. in Biology from Oakland University and an M.S. in Biochemistry from Wayne State University. Mr. Birndorf received honorary Doctor of Science degrees from Oakland University and Wayne State University.

David G. Ludvigson. In June of 2004, Mr. Ludvigson was appointed to his current position of President and Chief Operating
Officer. Mr. Ludvigson joined Nanogen full-time in May 2003 as Executive Vice President, Chief Financial Officer and Treasurer. Mr. Ludvigson was a director of Nanogen from 1996 until June 2003. Prior to joining Nanogen, he was President
and Chief Executive Officer of Black Pearl, Inc. (Black Pearl), an event-based business intelligence software company, from November 2001 until January, 2003. Prior to Black Pearl, from August 2000 to January 2001, Mr. Ludvigson was
President of InterTrust Technologies, a digital rights management software company. Prior to joining InterTrust Technologies, Mr. Ludvigson was a Senior Vice President and Chief Operating Officer of Matrix Pharmaceuticals, Inc.
(Matrix) from October 1999 to August 2000. In addition, from 1998 to August 2000 he was also the Chief Financial Officer of Matrix. From February 1996 to June 1998, Mr. Ludvigson was President and Chief Operating Officer of
NeTpower. From 1992 to 1995, Mr. Ludvigson was Senior Vice President and Chief Financial Officer of IDEC Pharmaceuticals. Prior to that time, he served as Senior Vice President of Sales and Marketing for Conner Peripherals and as Executive Vice
President, Chief Financial Officer and a director of MIPS Computer Systems, Inc., a RISC microprocessor developer and systems manufacturer. Mr. Ludvigson is also a Director of Jurilab, Ltd., HX Diagnostics and Kiyon, Inc. Mr. Ludvigson
received a B.S. and an M.A.S. from the University of Illinois.

Nicholas J. Venuto. Mr. Venuto joined Nanogen in June 2003 as
director of finance and was appointed the Chief Financial Officer effective in February 2008. He has over fifteen years of experience in finance, primarily focused in the life science and technology industries. Prior to joining the Company
and since January 2000, he held various senior finance and accounting roles at Graviton, Inc., most recently Vice President, Finance and



1



---

Corporate Secretary. From 1992 through 2000, Mr. Venuto served as a financial auditor for Ernst & Young LLP. He received a Bachelor
of Accounting degree from University of San Diego and is a Certified Public Accountant.

Graham Lidgard, Ph.D. Dr. Lidgard
joined Nanogen as Senior Vice President, Research and Development, in January 2003 and has over 28 years of experience in the Clinical Diagnostics industry. He was previously vice president of research and development at Gen-Probe from January 1995
to June 2002 where he led the R&D organization to develop DNA probe products for blood screening and STDs as well as the fully automated probe system, TIGRIS. Prior to Gen-Probe he was a co-founder of Matritech Inc., a cancer diagnostics
company in Massachusetts which he joined in January 1988, and held several positions with Coming Medical/Ciba Coming from July 1977 to January 1988 including program management, business development, marketing, technology acquisition and product
development. Dr. Lidgard received his Ph.D. and B.S. in Biological Chemistry from the University of Manchester.

William L.
Respess, Ph.D., J.D. Dr. Respess joined Nanogen as Senior Vice President, General Counsel, and Secretary, in April 2004 and has more than three decades of biotechnology experience in intellectual property, licensing and general
corporate law. His experience includes positions as Vice President and General Counsel of AME from 2002 to 2004, Senior Vice President and General Counsel of Graviton Incorporated from 2000 to 2002, Senior Vice President and General Counsel of
Ligand Pharmaceuticals Incorporated from 1988 to 2000, Vice President and General Counsel of Gen-Probe Incorporated from 1986 to 1988, Vice President and General Counsel of Hybritech Incorporated from 1983 to 1986 and Partner of Lyon & Lyon
LLP, a leading intellectual property law firm. He received his J.D. from George Washington University and served as Law Clerk and Technical Advisor to the Honorable J. Lindsay Almond, Jr., on the United States Court of Customs and Patent Appeals.
Dr. Respess also earned a Ph.D. in Organic Chemistry from Massachusetts Institute of Technology and a B.S. degree in Chemistry from Virginia Military Institute. He is a member of the American Intellectual Property Law Association and has been a
frequent lecturer on intellectual property and licensing law.

Directors of the Company

The names of and certain biographical information of our current external directors are as follows:

Robert E. Whalen. Mr. Whalen has been a director of Nanogen since April 2002. Mr. Whalen has been a Regional Vice President of Quest
Diagnostics since March 2003 and prior to the acquisition of Unilab Corporation (Unilab) by Quest Diagnostics in February 2003, was Chief Executive Officer, President and a director of Unilab from December 1999 to February 2003. He was
elected Chairman of the Board of Unilab in December 1999. From May 1997 to September 1999, Mr. Whalen served as Executive Vice President and, from September 1998 to September 1999, as Chief Operating Officer of Scripps Clinic, a
320-physician multi-specialty medical group located in Southern California. From the April 1995 merger of Roche Biomedical Laboratories and National Health Laboratories, Incorporated (NHL) until August 1996, Mr. Whalen served as
Executive Vice President of Laboratory Corporation of America (LabCorp). Prior to his employment at LabCorp, Mr. Whalen held various senior level positions with NHL, which he joined in 1976. He served as Executive Vice President of
NHL from 1993 to 1995, as Senior Vice President from 1991 to 1993 and as Vice President-Administration from 1985 to 1993. From 1979 to 1985, he was Vice President-Division Manager of NHL. At NHL and later at LabCorp, Mr. Whalen oversaw human
resources, client service and major regional laboratories in California, Washington, Nevada and Utah.

Stelios B. Papadopoulos.
Mr. Papadopoulos has been a director of Nanogen since October 1999. He retired in September 2001 from CN Biosciences, Inc. (CNBI), an affiliate of Merck KGaA, Darmstadt, Germany. From January 2001 to September 2001,
Mr. Papadopoulos served as Chief Executive Officer and a director of CNBI, and CEO of Merck KGaAs North American Laboratory Business. From August 2000 to December 2000 he acted as an assistant to the General Manager of Merck KGaAs
Scientific Laboratory Products Division. From January 1999 to August 2000, he served as the CEO of CNBI. From January 1993 to December 1999, he served as the Chairman and CEO of CNBI. He previously served as President of Fisher Scientific Worldwide,
Inc. (now



2



---

Fisher Scientific International Inc.) from April 1988 to June 1992. From October 1987 to April 1988, he was President of Instrumentation Laboratory. Since
March 2003, Mr. Papadopoulos has been serving as a director and as Chairman of the Audit Committee of US LABS, Inc. US LABS is a leading esoteric oncology and hematopathology laboratory. Mr. Papadopoulos received his B.S. in Aeronautical
Engineering from Northrop Institute of Technology.

David R. Schreiber. Mr. Schreiber has been a director of Nanogen since June
2003. Since 2006, Mr. Schreiber has served as CEO of Atherotech, Inc., a diagnostics laboratory company focused on expanding lipid testing. . From November 1996 to July 2003, Mr. Schreiber served as the Senior Vice President, Chief
Financial Officer and Secretary of Dianon Systems, Inc., a company that was acquired by the Laboratory Corporation of America (LabCorp.) in 2003 and from October 1999 to January, 2003, he served as a director of Dianon. From May 1994
until November 1996, Mr. Schreiber served as Vice President/General Manager-Midwest Region for Corning Clinical Laboratories, which is now Quest Diagnostics. From May 1990 to May 1994, he served as Vice President, Finance &
Administration at Unilab Corporation and from August 1986 to May 1990 he served as Regional Controller of the Midwest Region of Corning Clinical Laboratories. Mr. Schreiber received his B.S. in Finance with a minor in Economics in 1982 and his
MBA in 1984 from Northern Illinois University.

Heiner Dreismann. Dr. Dreismann has been a director of Nanogen since
October 31, 2006. Since 2006 Dr. Dreismann has served as the Chief Executive Officer of FasTraq, Inc. From 2000 to 2006, prior to joining the Company, he served as President and Chief Executive Officer of Roche Molecular Systems, Inc., an
affiliate of the Roche Group. Dreismann held a number of additional positions at Roche, including head of global business development, head of business unit PCR Europe, and head of business unit microbiology, all for Roche Diagnostics.
Dr. Dreismann received his M.A. in biology and his Ph.D. in microbiology/molecular biology both from Westfalische Wilheims University in Munster, Germany.

Company Code of Business Conduct and Ethics

We have adopted a Code of Business Conduct and Ethics, a code of ethics that
applies to all employees, consultants and agents including our executive officers and directors. A copy of the Code of Business Conduct and Ethics is posted on our Internet site at www.nanogen.com. In the event we make any amendments to, or
grant any waivers of, a provision of the Code of Business Conduct and Ethics that applies to the principal executive officer, principal financial officer, or principal accounting officer that requires disclosure under applicable SEC rules, we intend
to disclose such amendment or waiver on our website at www.nanogen.com.



|Item 11. | Executive Compensation
|-------- | ----------------------

Compensation
Discussion and Analysis

Introduction.It is our intent in this Compensation Discussion and Analysis to inform our
shareholders of the policies and objectives underlying the compensation programs for our executive officers. Accordingly, we will address and analyze each element of the compensation provided to our chief executive officer, our chief financial
officer and the other executive officers named in the Summary Compensation Table which follows this discussion. We are engaged in a very competitive industry, and our success depends upon our ability to attract and retain qualified executives
through competitive compensation packages. The Compensation Committee of our board of directors administers the compensation programs for our executive officers with this competitive environment in mind. However, we believe that the compensation
paid to our executive officers should also be substantially dependent on our financial performance and the value created for our shareholders. For this reason, the Compensation Committee also utilizes our compensation programs to provide meaningful
incentives for the attainment of our short-term and long-term strategic objectives and thereby reward those executive officers who make a substantial contribution to the attainment of those objectives.



3



---

In 2006, the Compensation Committee undertook a comprehensive review of the compensation programs in
effect for our executive officers in order to assess the competitiveness of those programs and to align such compensation with the longer term interests of our shareholders. In conducting this review, the Compensation Committee relied significantly
on the work of Frederic W. Cook & Co (FWC), an independent compensation consulting firm engaged directly by the Compensation Committee. FWC reviewed all of the compensation programs in effect for our executive officers,
including the compensation and benefits provided under their employment agreements. For purposes of measuring the competitiveness of the various elements of compensation provided under such programs and employment agreements, the Compensation
Committee relied primarily on compensation data derived by FWC from the most current proxy statements of an identified peer group comprised of fourteen small-cap diagnostics companies. The 14 companies within such peer group were as follows:



|                        |  |                           
|----------------------- |  | --------------------------
|Biosite, Inc.           |  | Solexa, Inc.              
|Molecular Devices Corp. |  | EXACT Sciences Corporation
|Digene Corporation      |  | BioVeris Corporation      
|Stratagene              |  | Third Wave Technologies   
|Quidel Corporation      |  | Luminex Corporation       
|Caliper                 |  | Monogram Biosciences, Inc.
|Cepheid                 |  | Clinical Data, Inc.       

For supplemental market data, the Compensation Committee also reviewed in 2006 and in 2007 the
Radford Biotechnology survey of executive officer compensation levels at companies with 150-to-500 employees within our industry as well as those in similar industries that compete with us for executive talent. While some changes resulting from this
comprehensive review were made in 2006, such as the award of stock option grants with performance-milestone vesting, the recommendations the Compensation Committee received from FWC were primarily implemented in connection with the compensation
programs established for the 2007 fiscal year, as described below.

Compensation Policy for Executive Officers. We
have designed the various elements comprising the compensation packages of our executive officers to achieve the following objectives:



| |  |  | attract, retain, motivate and engage executives with superior leadership and management capabilities,
| | - |  | -----------------------------------------------------------------------------------------------------



| |  |  | provide an overall level of compensation to each executive officer which is externally competitive, internally equitable and performance-driven, and
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | ensure that total compensation levels are reflective of our financial performance and provide the executive officer with the opportunity to earn above-market total
compensation for exceptional business performance.
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Each executive officers compensation package typically consists
of three elements: (i) a base salary, (ii) a cash bonus based upon participation in a bonus pool tied to our attainment of pre-established financial objectives and, where appropriate, the individual officers personal performance, and
(iii) participation in long-term, stock-based incentive awards, in the form of stock options and restricted stock unit awards, designed to align and strengthen the mutuality of interests between our executive officers and our shareholders. In
determining the appropriate level for each element of such compensation, the Compensation Committee has generally followed the practice of setting the compensation levels for our executive officers between the fiftieth and the seventy-fifth
percentiles of the compensation levels in effect for comparable positions of the peer group companies. However, the Compensation Committee also takes into account the Companys overall financial performance and its evaluation of each executive
officers individual performance level and his or her potential contribution to the Companys future growth. Accordingly, an executive officers actual compensation may be higher or lower than the targeted fiftieth to seventy-fifth
percentile range for his or her position. Consistent with our philosophy of emphasizing pay for performance, the overall objective of the cash compensation programs for our executive officers is to pay above the target when the Company exceeds its
goals and below the target when the Company does not achieve its goals.



4



---

Officer Employment Agreements.

In February, 2007 we entered into a series of employment agreements with our executive officers. Some of those agreements were in the form of an amendment
and restatement of their existing employment agreements with us. The remaining agreements were intended to formalize the terms of the original offer letters which certain of our officers received from us in lieu of employment agreements and to
adjust their individual compensation packages to assure that the elements of compensation provided to each of our executive officers remain uniform and consistent. For purposes of measuring the competitive levels of the various elements of our
executive officer employment agreements, the Compensation Committee relied primarily on the peer group compensation data provided by FWC.

Under our prior agreements with our executive officers, certain benefits were triggered upon the occurrence of a change of control event. Based on the recommendations of FWC, the 2007 employment agreements impose a double-trigger
requirement (change in control and an involuntary termination) for the payment of change in control benefits. The double trigger severance benefits under the 2007 agreements are larger than those that were previously in effect under the single
trigger agreements and require the executive to execute a general release. Those severance benefits include includes 12 months (24 months for Mr. Birndorf, and 18 months for Mr. Ludvigson) of salary continuation, the accelerated vesting of
outstanding equity awards, a pro-rated bonus and continued health care coverage at our expense for a designated period. A limited tax gross-up payment will be provided to compensate the executive officer for the portion of any parachute tax he or
she may incur as a result of the accelerated vesting of his or her pre-December 2006 equity awards, but the 2007 agreements do not extend this tax gross-up payment to awards made after December 2006 or to the other benefits provided under the
employment agreements.

For termination situations which are not associated with a change in control, the basic severance benefits are in
the form of salary continuation and medical coverage over a six-month period (eighteen months for Mr. Birndorf). In addition, 50% of Mr. Respess unvested stock options will vest on an accelerated basis.

We believe that the change from single trigger to double trigger agreements and enhancement of the double trigger severance package is fair and
reasonable in consideration of the dedication and commitment that the executive officers have rendered us over their years of service and the value we expect to receive from retaining their services prior to, and during, what we believe would be a
complex and challenging transition period following a change of control transaction. The acceleration of their outstanding equity awards is also appropriate in our view, because those awards are designed to serve as the primary vehicle for the
executive officers to accumulate financial resources for retirement. We do not provide our executive officers with any defined benefit pension plans or supplemental executive retirement plans, and the only other opportunity for the accumulation of
retirement income is through the limited deferral of compensation under our 401(k) savings plan. In addition, FWC advised the Compensation Committee that the double trigger severance package provided under the 2007 employment agreements was within
the competitive range of comparable severance benefits for executive officers at other companies of similar size and market capitalization.

We also believe that the employment agreements with our executive officers achieve two important goals crucial to our long-term financial success, namely, the long-term retention of our senior executives and their commitment to the
attainment of our strategic objectives. The agreements will allow our participating executive officers to continue to focus their attention on our business operations and strategic plans without undue concern over their own financial situations
during periods when substantial disruptions and distractions might otherwise prevail.

In December 2007, Robert Saltmarsh, the Vice
President and Chief Financial Officer, notified the Company of his decision to retire at the end of February 2008. We promoted Nicholas Venuto, our then Executive Director of Finance, to the position of Vice President and Chief Financial Officer,
effective in February, 2008. In connection with his promotion, the Compensation Committee increased Mr. Venutos annual base salary from $183,000 to $220,000 and granted him an option to purchase 100,000 shares of the Companys common
stock at



5



---

an exercise price of $0.485 per share, the fair market value of the Companys common stock on the option grant date. The option vests in equal monthly
installments over a four year period. In February 2008, we entered into a formal employment agreement with Mr. Venuto, which is substantially similar to the agreement we entered into in February 2007 with our other executive officers. For
purposes of measuring the competitive level of Mr. Venutos compensation package, the Compensation Committee relied primarily on compensation data from the Radford Group survey of executive officer compensation levels. Based on this data,
the Compensation Committee concluded that Mr. Venutos compensation was between the 10thand 25thpercentile levels when compared to chief financial officer positions within the peer group.

A summary of the material terms of the officer employment agreements, together with a quantification of the severance benefits payable under those agreements to each of the executive officers named in the Summary
Compensation Table and Mr. Venuto, may be found in the section of the proxy statement entitled Executive Compensation and Other InformationEmployment Contracts, Termination of Employment and Change in Control Arrangements.

Comparative Framework.For purposes of measuring the competitive levels of the various components of our executive officer
compensation program for the 2007 fiscal year, the Compensation Committee relied primarily on the peer group data provided by FWC and, to a lesser extent, on survey data from the Radford Group survey of executive officer compensation levels at
companies that are within our industry or in similar industries and are comparable in size with us and compete with us for executive talent. The Compensation Committee also reviewed the Biotech Employment Development Coalition (BEDC)
survey of executive officer compensation levels at San Diego area biotech related businesses that are comparable in size and also compete with us for executive talent.

In analyzing the comparative market data, the Compensation Committee reviewed the compensation data provided by FWC, the Radford Group and BEDC surveys with respect to base salary and bonus.

It is our objective to target the various elements of the compensation package provided each of our executive officers at the following percentiles when
compared to those three primary sources of comparative market data for the year:



|                        |  |                                    
|----------------------- |  | -----------------------------------
|Base Salary             |  | Between the 50th and 75thPercentile
|Total Cash Compensation |  | Between the 50th and 75thPercentile

Comparative Analysis for 2007.When compared to the peer group data provided
by FWC, the elements of cash compensation provided to our executive officers for the 2007 fiscal year were at the following percentiles for most of our executive officers:



|                        |  |                                    
|----------------------- |  | -----------------------------------
|Base Salary             |  | Between the 50th and 75thPercentile
|Total Cash Compensation |  | Between the 50th and 75thPercentile

Elements of Compensation. Each of the three major elements comprising the
compensation package for executive officers (salary, bonus and equity) is designed to achieve one or more of our overall objectives in fashioning a competitive level of compensation, tying compensation to the attainment of one or more of our
strategic business objectives and subjecting a substantial portion of the executive officers compensation to our financial success as measured in terms of our stock price performance. The manner in which the Compensation Committee has so
structured each element of compensation may be explained as follows.

Salary. The Compensation Committee reviews the base
salary level of each executive officer in the first quarter each year, with any salary adjustments for the year to be made retroactive to January 1 of that year. The base salary for the executive officers named in the Summary Compensation Table
is determined on the basis of their level of responsibility, experience and individual performance. The Compensation Committee believes that



6



---

this component of compensation should provide a level of security and stability from year to year and not be dependent to any material extent on the
Companys financial performance. In addition, each of the named executive officers has an existing employment agreement with the Company which sets a minimum annual salary, subject to periodic upward adjustment at the discretion of the
Compensation Committee. The salary level for the named executive officers was increased in 2007 by 3% from the level in effect for the 2006 fiscal year based on analysis of comparable salaries and the local job market conditions. For the 2007 fiscal
year, the salary levels for our executive officer group ranged from a high of $520,000 to a low of $258,000.

However, in order to preserve
the Companys cash resources, no salary increases were affected for the 2008 fiscal year. Instead, the each of the named executive officers were granted additional stock options, as described under the heading Long-Term Incentives
below.

Incentive Compensation. For the 2007 fiscal year, the Compensation Committee implemented the 2007 Executive Officer
Incentive Compensation Plan (the 2007 Incentive Plan), designed to advance our pay-for-performance policy by focusing the attention of our executive officers on the attainment of key operational objectives for the year. The plan provided
all of our executive officers with a direct financial incentive in the form of a bonus award to be paid in cash, stock or a combination thereof tied to our achievement of two pre-established operational goals.

The operational goals were tied to the following measures of our financial performance for the 2007 fiscal year, weighted as indicated: revenue (30%
weighting) and EBITDA (70% weighting). For each executive officer, bonus opportunities were established at threshold, target and maximum levels of attainment of each of the operational goals. Any bonuses earned on the basis of the attained levels
were to be paid from a bonus pool in a dollar amount not to exceed $1,236,000 for the 2007 fiscal year.

The various levels of attainment
established for the revenue and EBITDA operational goals for the 2007 fiscal year (the 2007 Operational Goals) were as follows:



|                            |  |           |   |  |        |   |  |         |  
|--------------------------- |  | --------- | - |  | ------ | - |  | ------- | -
|                            |  | Threshold |   |  | Target |   |  | Maximum |  
|Revenue ($ in millions)     |  | 37.5      |   |  | 43.2   |   |  | 48.5    |  
|EBITDA ($ loss in millions) |  | (25.6     | ) |  | (22.4  | ) |  | (19.0   | )

The dollar amount of the potential bonus at each of the various levels of attainment of the 2007
Operational were as follows for the named executive officers:



|                 |  |                  |  |               |  |            |  |            
|---------------- |  | ---------------- |  | ------------- |  | ---------- |  | -----------
|Name             |  | Performance Goal |  | Threshold ($) |  | Target ($) |  | Maximum ($)
|Howard Birndorf  |  | Revenue          |  | 46,814        |  | 93,627     |  | 140,441    
|                 |  | EBITDA           |  | 109,232       |  | 218,463    |  | 327,695    
|                 |  |                  |  |              
|David Ludvigson  |  | Revenue          |  | 27,038        |  | 54,075     |  | 81,113     
|                 |  | EBITDA           |  | 63,088        |  | 126,175    |  | 189,263    
|                 |  |                  |  |              
|Graham Lidgard   |  | Revenue          |  | 8,714         |  | 17,428     |  | 26,141     
|                 |  | EBITDA           |  | 20,332        |  | 40,664     |  | 60,997     
|                 |  |                  |  |              
|Larry Respess    |  | Revenue          |  | 19,776        |  | 39,552     |  | 59,328     
|                 |  | EBITDA           |  | 46,144        |  | 92,288     |  | 138,432    
|                 |  |                  |  |              
|Robert Saltmarsh |  | Revenue          |  | 15,450        |  | 30,900     |  | 46,350     
|                 |  | EBITDA           |  | 36,050        |  | 72,100     |  | 108,150    

For Mr. Lidgard, our Senior Vice President, Research and Development, the Compensation
Committee deemed it advisable to tie fifty percent of his bonus award to his accomplishment of specific individual performance goals. Accordingly, for Mr. Lidgard only, 50% of his target bonus under the Incentive Plan was based on company
performance tied to the 2007 Operational Goals and the other 50% was tied his accomplishment of the following pre-determined individual performance objectives intended to focus his



7



---

attention on the achievement of the following product development milestones: meet the new product development plan for the NC400 microarray, real-time PCR
and Point of Care businesses; meet cash flow management objectives including budgeted expenses and contract revenues; support the implementation of alternative business strategies including partnerships and OEM product opportunities.

For the purposes of determining whether the revenue and EBITDA objectives were met for the 2007 fiscal year, the Compensation Committee used the numbers
we reported for financial statement purposes in accordance with generally accepted accounting principles in the U.S. (GAAP), adjusted for non-cash, non-recurring, extraordinary items and certain other items. The Compensation
Committees determination as to whether Mr. Lidgards product development milestones were met was based on the input received from our Chief Executive Officer and our President and further discussions with them. In February 2008, the
Compensation Committee determined that our financial performance for the 2007 year was at 51% level for the revenue goal, at 0% level for the EBITDA goal, and Mr. Lidgards product development milestones had been partially met. Accordingly
the Compensation Committee awarded incentive bonuses totaling $146,838 from the pool. The actual 2007 bonuses were paid either in cash or in shares of our common stock at the recipients election, with the shares of common stock to be valued at
the closing price on the second trading day after the announcement of financial results for the period ended December 31, 2007.

For
the 2008 fiscal year, the Compensation Committee approved the 2008 Executive Officer Incentive Compensation Plan, designed to focus the attention of our executive officers on the attainment of the following measures of our financial performance for
the 2008 fiscal year, weighted as indicated: revenue (30% weighting), EBITDA (50% weighting) and Fourth Quarter EBITDA (20% weighting). For each executive officer, bonus opportunities were established for each goal at threshold, target and
above-target levels of attainment, with the actual bonuses earned under such plan to be paid from a bonus pool in a dollar amount not to exceed $1,236,000 for the 2008 fiscal year.

To ensure a smooth transition in connection with Mr. Saltmarshs retirement from his position with the Company as Vice President and Chief
Financial Officer and Mr. Venutos promotion to such position, the Company approved a cash retention bonus in December 2007 in the amount of $65,000 to be paid to Mr. Saltmarsh on February 28, 2008, provided he remained in the
Companys employ through such date. Mr. Saltmarsh remained employed by the Company through such date and accordingly received the retention bonus.

Long-Term Incentives. We have structured our long-term incentive program for executive officers in the form of equity awards under our amended and restated 1997 Stock Incentive Plan. For many years stock option
grants were the sole form of equity award granted to our executive officers, and we continue to use stock option grants in combination with other forms of equity awards available under the 1997 plan to provide long-term incentives to our executive
officers. Each grant is designed to align the interests of the executive officer with those of the shareholders and to provide each individual with a significant incentive to manage the company from the perspective of an owner with an equity stake
in the business. Each grant allows the officer to acquire shares of our common stock at a fixed price per share (the closing selling price on the grant date) over a specified period, usually ten years. Options granted in past years generally vest
and become exercisable in a series of installments over a two-year period measured from the grant date, contingent upon the officers continued employment. Accordingly, each option will provide a return to the executive officer only to the
extent he remains employed with us during the vesting period, and then only if the fair market value of the underlying shares appreciates over the period between grant and exercise of the option.

We award restricted stock units (RSUs) as part of our long-term incentive program. We believe that RSUs are a valuable component of our
long-term incentive program for several reasons, including ongoing concerns over the dilutive effect of option grants on our outstanding shares, our desire to have a more direct correlation between the FAS 123(R) compensation expense we must take
for financial accounting purposes and the actual value delivered to our executive officers and other employees pursuant to an equity grant, and the fact that the



8



---

incentive effects of RSUs are less subject to market volatility than stock options. Each RSU entitles the recipient to one share of our common stock at the
time of vesting without the payment of an exercise price or other consideration. The vesting of RSUs is tied to continued service with us, generally over a two-year period measured from the award date.

As part of the Companys pay for performance philosophy and in accordance with FWCs recommendation, the Compensation Committee made a special
stock option award to each our executive officers in December 2006 for the following number of shares: Mr. Birndorf, 280,000 shares; Mr. Ludvigson, 155,000 shares; Mr. Lidgard, 95,000 shares; Mr. Respess, 95,000 shares; and
Mr. Saltmarsh, 95,000 shares. Each option has an exercise price per share equal to the fair market value of our common stock on the option grant date and will vest on the achievement of aggressive revenue and EBITDA targets within a five and a
half year period measured from the grant date. In addition, each option contains a vesting acceleration provision pursuant to which 50% of the option will vest upon a change in control, and 100% will vest if the change in control is at a price per
share of our common stock above a pre-set target price.

In February 2007, the Compensation Committee also structured the annual stock
option grants to our executive officers so that vesting was tied to the attainment of pre-established performance objectives. Each option had an exercise price per share equal to the fair market value of the Companys common stock on the option
grant date and would vest in whole or in part on the basis of the levels at which the 2007 Operational Goals under the 2007 Incentive Plan were attained . Any options which vested on the basis of the attained levels of the 2007 Operational Goals
were subject to a further service vesting requirement over a four year period, with twenty-five percent of the option shares to vest upon the executive officers completion of one year of service measured from the grant date, and the remaining
option shares to vest monthly over the next thirty six months of continued service. To the extent the 2007 Operational Goals were not attained at the above-target levels, all or a portion of the option would be immediately forfeited at the close of
the 2007 fiscal year. The number of option shares allocated to each 2007 Operational Goal was as follows for the named executive officers:



|                 |  |                  |  |                                 |  |                              |  |                                   
|---------------- |  | ---------------- |  | ------------------------------- |  | ---------------------------- |  | ----------------------------------
|Name             |  | Performance Goal |  | ThresholdNumber ofOption Shares |  | Target Numberof OptionShares |  | Above TargetNumber ofOption Shares
|Howard Birndorf  |  | Revenue          |  | 54,750                          |  | 109,500                      |  | 164,250                           
|                 |  | EBITDA           |  | 127,750                         |  | 255,500                      |  | 383,250                           
|                 |  |                  |  |                                
|David Ludvigson  |  | Revenue          |  | 30,000                          |  | 60,000                       |  | 90,000                            
|                 |  | EBITDA           |  | 70,000                          |  | 140,000                      |  | 210,000                           
|                 |  |                  |  |                                
|Graham Lidgard   |  | Revenue          |  | 18,750                          |  | 37,500                       |  | 56,250                            
|                 |  | EBITDA           |  | 43,750                          |  | 87,500                       |  | 131,250                           
|                 |  |                  |  |                                
|Larry Respess    |  | Revenue          |  | 18,750                          |  | 37,500                       |  | 56,250                            
|                 |  | EBITDA           |  | 43,750                          |  | 87,500                       |  | 131,250                           
|                 |  |                  |  |                                
|Robert Saltmarsh |  | Revenue          |  | 18,750                          |  | 37,500                       |  | 56,250                            
|                 |  | EBITDA           |  | 43,750                          |  | 87,500                       |  | 131,250                           

Based on the Companys performance in 2007, the Compensation Committee determined that 16% of
the option shares had been earned and accordingly, only the following number of option shares subject to the February 2007 option grants remain outstanding:



|                |  |                       
|--------------- |  | ----------------------
|Name            |  | Number ofOption Shares
|Howard Birndorf |  | 21,900                
|David Ludvigson |  | 12,000                
|Graham Lidgard  |  | 7,500                 
|Larry Respess   |  | 7,500                 

Mr. Saltmarshs employment with the Company terminated prior to any of the February 2007
option grants becoming vested and exercisable; accordingly all of his February 2007 option shares have terminated.



9



---

In determining the total number of shares to award each executive officer in the combined form of stock
options and RSUs for the 2007 fiscal year, the Compensation Committee reviewed data provided by FWC, but the Compensation Committee did not seek to bring the total direct compensation (salary, bonus and equity) of each executive officer to a
specific percentile of the total direct compensation for comparable positions at the peer group companies.

In March 2008, the
Companys executive officers were granted performance-based stock options, subject to shareholder approval of an increase to the available reserve under the Corporations 1997 Stock Incentive Plan. The options will terminate prior to
becoming exercisable, to the extent the performance goals under the 2008 Executive Officer Incentive Compensation Plan are not attained at one or more pre-determined levels. To the extent earned, the options will vest over a four-year period, with
twenty-five percent of the option shares to vest upon the executive officers completion of one year of service measured from the grant date, and the remaining option shares to vest monthly over the next thirty six months of continued service
period measured from the first anniversary of the option grant date. The maximum number of option shares that can be earned pursuant to the March 2008 grant is as follows for each executive officer: Mr. Birndorf, 547,500 shares;
Mr. Ludvigson, 300,000 shares; Mr. Lidgard, 187,500 shares; Mr. Respess, 187,500 shares; and Mr. Venuto, 187,500 shares.

In March 2008, the Compensation Committee granted options for the following number of shares to each executive officer in lieu of a salary increase for the 2008 year: Mr. Birndorf, 208,547 shares; Mr. Ludvigson, 144,537 shares;
Mr. Lidgard, 116,546 shares; Mr. Respess, 132,148 shares; and Mr. Venuto, 0 shares. Each option will vest in a series of 48 successive equal monthly installments over a four year period of service measured from January 1, 2008.
Each option has an exercise price per shares equal to the closing price of our common stock on the grant date.

Market Timing of
Equity Awards. The Compensation Committee does not engage in any market timing of the equity awards made to the executive officers or other award recipients, and there is no established practice of timing our awards in advance of the release
of favorable financial results or adjusting the award date in connection with the release of unfavorable financial developments affecting our business. It is our intent that all stock option grants have an exercise price per share equal to the
closing selling price per share on the effective date of the grant.

Executive Officer Perquisites. It is not our
practice to provide our executive officers with any meaningful perquisites. We do, however, provide Mr. Birndorf with administrative assistant services for personal matters and supplemental medical and dental coverage under the Exec-U-Care
program. The dollar value of these perquisites was approximately $37,725 for the 2007 fiscal year.

Other Programs.
Our executive officers are eligible to participate in our 401(k) employee savings plan and our employee stock purchase plan on the same basis as all other regular U.S. employees.

Deferred Compensation Programs.We do not maintain any non-qualified deferred compensation programs for our executive officers or any
supplemental executive retirement plans. We believe that the equity award component of each executive officers total direct compensation package should serve as a major source of wealth creation, including the accumulation of substantial
resources to fund the executive officers retirement years.

Compliance with Internal Revenue Code
Section 162(m). Section 162(m) of the Internal Revenue Code disallows a tax deduction to publicly held companies for compensation paid to certain of their executive officers to the extent such compensation exceeds $1.0
million per covered officer in any year. The limitation applies only to compensation that is not considered to be performance-based under the terms of Section 162(m). The stock options granted to our executives are intended to qualify as
performance based compensation. Non-performance-based compensation paid to our executive officers for 2007 did not exceed the $1.0 million limit per officer. However, as we continue to use service-vesting restricted stock units as a component of
equity compensation, it



10



---

is likely that the non-performance-based compensation payable to our executive officers will exceed the $1.0 million limit in one or more future years. We
believe that in establishing the cash and equity incentive compensation programs for our executive officers, the potential deductibility of the compensation payable under those programs should be only one of a number of relevant factors taken into
consideration, and not the sole governing factor. For that reason, we may deem it appropriate to provide one or more executive officers with the opportunity to earn incentive compensation, whether through cash bonus programs tied to our financial
performance or through RSUs tied to the executive officers continued service, which together with base salary in the aggregate may be in excess of the amount deductible by reason of Section 162(m) or other provisions of the Internal Revenue
Code. We believe it is important to maintain cash and equity incentive compensation at the levels needed to attract and retain the executive officers essential to our success, even if all or part of that compensation may not be deductible by reason
of the Section 162(m) limitation.

Summary Compensation Information

The following table provides certain summary information concerning the compensation earned for services rendered in all capacities to the Company and its subsidiaries for the year ended December 31, 2007 by the
Companys Chief Executive Officer, Chief Financial Officer and each of the Companys three other most highly compensated executive officers whose total compensation for the 2007 year was in excess of $100,000 and who were serving as
executive officers at the end of the 2007 Fiscal Year. No other executive officers who would have otherwise been includable in such table on the basis of total compensation for the 2007 Fiscal Year have been excluded by reason of their termination
of employment or change in executive status during that year. The listed individuals shall be hereinafter referred to as the named executive officers. The Company does not sponsor a pension plan or a non-qualified deferred compensation
plan.



|                                                     |  |      |  |              |         |             |        |     |                   |   |                    |  |                                             |         |                         |   |         |          |   |        |     |  |   |          
|---------------------------------------------------- |  | ---- |  | ------------ | ------- | ----------- | ------ | --- | ----------------- | - | ------------------ |  | ------------------------------------------- | ------- | ----------------------- | - | ------- | -------- | - | ------ | --- |  | - | ---------
|Name and Principal Position                          |  | Year |  | Salary($)(1) |         | Bonus($)(1) |        |     | StockAwards($)(2) |   | OptionAwards($)(3) |  | Non- EquityIncentive PlanCompensation($)(4) |         | AllOtherCompensation($) |   |         | Total($)
|(a)                                                  |  | (b)  |  | (c)          |         | (d)         |        |     | (e)               |   | (f)                |  | (g)                                         |         | (h)                     |   |         | (i)     
|Howard C.Birndorf,                                   |  | 2007 |  | $            | 520,150 |             |       |     |                   | $ | 230,932            |  | $                                           | 100,814 |                         | $ | 46,814  |          | $ | 37,725 | (5) |  | $ | 936,435  
|Chairman and Chief Executive Officer                 |  | 2006 |  | $            | 505,000 |             |       |     |                   | $ | 225,337            |  | $                                           | 445,382 |                         | $ | 148,470 |          | $ | 34,319 |     |  | $ | 1,358,508
|                                                     |  |      |  |              |         |             |        |    
|David G. Ludvigson,                                  |  | 2007 |  | $            | 360,500 |             |       |     |                   | $ | 115,466            |  | $                                           | 422,812 |                         | $ | 27,038  |          | $ | 5,516  | (6) |  | $ | 931,332  
|President and Chief Operating Officer                |  | 2006 |  | $            | 350,000 |             |       |     |                   | $ | 112,669            |  | $                                           | 600,559 |                         | $ | 85,750  |          | $ | 4,850  |     |  | $ | 1,153,828
|                                                     |  |      |  |              |         |             |        |    
|Robert Saltmarsh,                                    |  | 2007 |  | $            | 257,500 |             |       |     |                   | $ | 57,733             |  | $                                           | 185,281 |                         | $ | 15,450  |          | $ | 6,266  | (6) |  | $ | 522,230  
|Former Vice President and Chief Financial Officer(7) |  | 2006 |  | $            | 250,000 |             |       |     |                   | $ | 56,334             |  | $                                           | 206,224 |                         | $ | 49,000  |          | $ | 6,100  |     |  | $ | 567,658  
|                                                     |  |      |  |              |         |             |        |    
|William L. Respess,                                  |  | 2007 |  | $            | 329,600 |             |       |     |                   | $ | 57,733             |  | $                                           | 254,988 |                         | $ | 19,776  |          | $ | 11,180 | (6) |  | $ | 673,277  
|Senior Vice President, General Counsel and Secretary |  | 2006 |  | $            | 320,000 |             |       |     |                   | $ | 56,334             |  | $                                           | 322,187 |                         | $ | 62,720  |          | $ | 7,100  |     |  | $ | 768,341  
|                                                     |  |      |  |              |         |             |        |    
|Graham Ligard,                                       |  | 2007 |  | $            | 290,600 |             | 29,046 | (8) |                   | $ | 57,733             |  | $                                           | 8,485   |                         | $ | 8,714   |          | $ | 6,266  | (6) |  | $ | 400,844  
|Senior Vice President, Research and Development      |  | 2006 |  | $            | 282,000 |             | 36,660 | (9) |                   | $ | 56,334             |  | $                                           | 168,115 |                         | $ | 27,636  |          | $ | 7,100  |     |  | $ | 577,845  



|(1) | Includes amounts deferred at the named executive officers election under the Companys 401(k) Defined Contribution Savings and Retirement Plan, a qualified deferred
compensation plan under section 401(k) of the Internal Revenue Code.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(2) | The amounts in column (e) do not reflect actual value received by the officer in 2007 and 2006, but rather reflect the dollar amount recognized for financial statement
reporting purposes for the fiscal years ended December 31, 2007 and 2006, in accordance with FAS 123(R) of stock awards granted to each named executive officer and thus include amounts from awards granted in and prior to the applicable year.
Assumptions used in the calculation of these amounts are included in footnote 8 to the Companys audited financial statements for the fiscal year ended December 31, 2007 included in the Companys Annual Report on Form 10-K filed with
the Securities and Exchange Commission on March 31, 2008.
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(3) | The amounts in column (f) do not reflect actual proceeds received, but rather these amounts reflect the dollar amount recognized for financial statement reporting purposes for
the fiscal years ended December 31, 2007 and 2006, in accordance with FAS 123(R) of stock options granted to each named executive officer and thus include amounts from awards granted in and prior to the applicable year. Assumptions used in the
calculation of this amount are included in footnote 8 to the Companys audited financial statements for the fiscal year ended December 31, 2007 included in the Companys Annual Report on Form 10-K filed with the Securities and
Exchange Commission on March 31, 2007.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



11



---

|(4) | The amounts in column (g) for the 2007 fiscal year reflect the cash awards to the named executive under the Companys 2007 Executive Officer Incentive Compensation Plan
which is described in detail under the heading Incentive Compensation on page [            ].
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(5) | The amount shown includes (i) $29,375, which represents the aggregate incremental cost to the company of administrative assistance service provided by the Company to
Mr. Birndorf for his personal use, (ii) the premiums and miscellaneous expenses paid by the Company for supplemental medical and dental coverage provided to Mr. Birndorf under the Exec-U-Care program, which is in addition to the
medical and dental coverage provided to all employees of the Company and (iii) the dollar value of life insurance premiums paid by the Company on behalf of Mr. Birndorf.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(6) | Includes (i) the fair market value of shares of our common stock contributed as a matching contribution by the Company to the named executive officers account under our
401(k) Defined Contribution Savings and Retirement plan on the date the matching contribution was approved by the Compensation Committee and (ii) the dollar value of life insurance premiums paid by the Company on behalf of the named executive
officer.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(7) | Mr. Saltmarsh retired from his position as Vice President and Chief Financial Officer in February 2008.
|--- | -------------------------------------------------------------------------------------------------------

|(8) | Reflects the portion of the cash award to Mr. Lidgard under the Companys 2007 Executive Officer Incentive Compensation Plan which was paid as a result of
Mr. Lidgards personal performance. The 2007 Executive Officer Incentive Compensation Plan is described in detail under the heading Incentive Compensation on page
[            ].
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(9) | Reflects the portion of the cash award to Mr. Lidgard under the Companys 2006 Executive Officer Incentive Compensation Plan which was paid as a result of
Mr. Lidgards personal performance.
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



12



---

Grants of Plan-Based Awards

The following table provides certain summary information concerning each grant of an award made to a named executive officer in the 2007 Fiscal Year
under a compensation plan.



|                                                                         |           |              |   |                                                                    |   |                                                               |   |              |                                           |           |                                |            |         |     |  |      |     |         |    
|------------------------------------------------------------------------ | --------- | ------------ | - | ------------------------------------------------------------------ | - | ------------------------------------------------------------- | - | ------------ | ----------------------------------------- | --------- | ------------------------------ | ---------- | ------- | --- |  | ---- | --- | ------- | ---
|Name                                                                     |           | Grant Date   |   | Estimated Possible Payouts UnderNon-Equity Incentive PlanAwards(1) |   | Estimated Future Payouts UnderEquity Incentive Plan Awards(2) |   |              | Exerciseor BasePrice ofOptionAwards($/Sh) |           | GrantDateFAS123(R)FairValue($)
|                                                                         |           | Threshold($) |   | Target($)                                                          |   | Maximum($)                                                    |   | Threshold(#) |                                           | Target(#) |                                | Maximum(#) |         |     | 
|(a)                                                                      |           | (b)          |   | (c)                                                                |   | (d)                                                           |   | (e)          |                                           | (f)       |                                | (g)        |         | (h) |  |      | (i) |         | (j)
|Howard Birndorf, Chairman and Chief Executive Officer                    |           | 2/16/2007    |   | 156,045                                                            |   | 312,090                                                       |   | 468,135      |                                           |          |                                |           |         |    |  |      |    |         |   
|                                                                         | 2/16/2007 |              |  |                                                                    |  |                                                               |  |              | 182,500                                   |           | 365,000                        |            | 547,500 | (2) |  | 1.39 |     | 558,107
|                                                                         |           |              |   |                                                                    |   |                                                               |   |              |                                          
|David G. Ludvigson, President and Chief Operating Officer                |           | 2/16/2007    |   | 90,125                                                             |   | 180,250                                                       |   | 270,375      |                                           |          |                                |           |         |    |  |      |    |         |   
|                                                                         | 2/16/2007 |              |  |                                                                    |  |                                                               |  |              | 100,000                                   |           | 200,000                        |            | 300,000 | (2) |  | 1.39 |     | 305,812
|                                                                         |           |              |   |                                                                    |   |                                                               |   |              |                                          
|Robert Saltmarsh, Chief Financial Officer                                |           | 2/16/2007    |   | 51,500                                                             |   | 103,000                                                       |   | 154,500      |                                           |          |                                |           |         |    |  |      |    |         |   
|                                                                         | 2/16/2007 |              |  |                                                                    |  |                                                               |  |              | 62,500                                    |           | 125,000                        |            | 187,500 | (2) |  | 1.39 |     | 191,133
|                                                                         |           |              |   |                                                                    |   |                                                               |   |              |                                          
|William L. Respess, Senior Vice President, General Counsel and Secretary |           | 2/16/2007    |   | 65,920                                                             |   | 131,840                                                       |   | 197,760      |                                           |          |                                |           |         |    |  |      |    |         |   
|                                                                         | 2/16/2007 |              |  |                                                                    |  |                                                               |  |              | 62,500                                    |           | 125,000                        |            | 187,500 | (2) |  | 1.39 |     | 191,133
|                                                                         |           |              |   |                                                                    |   |                                                               |   |              |                                          
|Graham Lidgard, Senior Vice President, Research and Development          |           | 2/16/2007    |   | 58,092                                                             |   | 116,184                                                       |   | 174,276      |                                           |          |                                |           |         |    |  |      |    |         |   
|                                                                         | 2/16/2007 |              |   |                                                                    |  |                                                               |   |              | 62,500                                    |           | 125,000                        |            | 187,500 | (2) |  | 1.39 |     | 191,133



|(1) | Reflects the potential payouts under the Companys 2007 Executive Officer Incentive Compensation Plan based on Company performance during the 2007 year, and assumes that for
each level of achievement each of the three operational goals were achieved at that level. The actual amounts earned under such plan are disclosed in the Summary Compensation Table in the column Non-Equity Incentive Plan Compensation.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(2) | Reflects stock options granted under the Companys 1997 Stock Incentive Plan, which vest based on the levels at which the goals under the 2007 incentive Plan were attained. Any
options which vested on the basis of the attained levels of the 2007 Incentive Plan are subject to a further service vesting requirement over a four year period, with twenty-five percent of the option shares to vest upon the executive officers
completion of one year of service measured from the grant date, and the remaining option shares to vest monthly over the next thirty-six months of continued service. The actual number of option shares earned under such awards is disclosed in the
Compensation Discussion and Analysis under the heading Long-Term Incentives.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



13



---

Outstanding Equity Awards at Fiscal Year-End

The following table provides certain summary information concerning outstanding equity awards held by the Named Executive Officers as of
December 31, 2007.



|                                                          |                                                                |               |                                                                  |              |  |                                                                                        |         |  |                        |      |                      |           |                                                        |        |  |                                                                 |       
|--------------------------------------------------------- | -------------------------------------------------------------- | ------------- | ---------------------------------------------------------------- | ------------ |  | -------------------------------------------------------------------------------------- | ------- |  | ---------------------- | ---- | -------------------- | --------- | ------------------------------------------------------ | ------ |  | --------------------------------------------------------------- | ------
|Name(7)                                                   |                                                                | Option Awards |                                                                  | Stock Awards
|                                                          | Number ofSecuritiesUnderlyingUnexercisedOptions (#)Exercisable |               | Number ofSecuritiesUnderlyingUnexercisedOptions (#)Unexercisable |              |  | EquityIncentivePlan Awards:Number ofSecuritiesUnderlyingUnexercisedUnearnedOptions
(#) |         |  | OptionExercisePrice($) |      | OptionExpirationDate |           | Number ofShares orUnits ofStock ThatHave NotVested (#) |        |  | Market Valueof Shares orUnits of StockThat
HaveNot Vested($)(8)
|(a)                                                       |                                                                | (b)           |                                                                  | (c)          |  |                                                                                        | (d)     |  |                        | (e)  |                      | (f)       |                                                        | (g)    |  |                                                                 | (h)   
|Howard Birndorf, Chairman and Chief Executive Officer     |                                                                | 25,000        |                                                                  |             |  |                                                                                        |        |  |                        | 4.50 |                      | 1/22/2009 |                                                        |       |  |                                                                 |      
|                                                          | 80,000                                                         |               |                                                                 |              |  |                                                                                       |         |  | 11.94                  |      | 1/25/2011            |           |                                                       |        |  |                                                               
|                                                          | 70,000                                                         |               |                                                                 |              |  |                                                                                       |         |  | 6.00                   |      | 7/26/2011            |           |                                                       |        |  |                                                               
|                                                          | 22,694                                                         |               |                                                                 |              |  |                                                                                       |         |  | 5.11                   |      | 1/24/2012            |           |                                                       |        |  |                                                               
|                                                          | 127,306                                                        |               |                                                                 |              |  |                                                                                       |         |  | 5.11                   |      | 1/24/2012            |           |                                                       |        |  |                                                               
|                                                          | 400,000                                                        |               |                                                                 |              |  |                                                                                       |         |  | 1.90                   |      | 7/25/2012            |           |                                                       |        |  |                                                               
|                                                          | 325,000                                                        |               |                                                                 |              |  |                                                                                       |         |  | 3.45                   |      | 7/17/2013            |           |                                                       |        |  |                                                               
|                                                          | 17,878                                                         |               |                                                                 |              |  |                                                                                       |         |  | 4.70                   |      | 7/28/2014            |           |                                                       |        |  |                                                               
|                                                          | 282,122                                                        |               |                                                                 |              |  |                                                                                       |         |  | 4.70                   |      | 7/28/2014            |           |                                                       |        |  |                                                               
|                                                          | 22,727                                                         |               |                                                                 |              |  |                                                                                       |         |  | 4.40                   |      | 7/28/2015            |           |                                                       |        |  |                                                               
|                                                          | 127,273                                                        |               |                                                                 |              |  |                                                                                       |         |  | 4.40                   |      | 7/28/2015            |           |                                                       |        |  |                                                               
|                                                          |                                                               |               |                                                                 |              |  | 280,000                                                                                | (1)     |  | 2.09                   |      | 12/12/2016           |           |                                                       |        |  |                                                               
|                                                          |                                                               |               |                                                                 |              |  | 547,500                                                                                | (2)     |  | 1.39                   |      | 2/16/2017            |           |                                                       |        |  |                                                               
|                                                          |                                                               |               |                                                                 |              |  |                                                                                       |         |  |                       |      |                     |           | 50,000                                                 | (3)    |  | 18,000                                                         
|                                                          |                                                                |               |                                                                  |              |  |                                                                                        |         |  |                        |      |                      |           |                                                        |        |  |                                                                 |       
|                                                          |                                                                | 1,500,000     |                                                                  |             |  |                                                                                        | 827,500 |  |                        |      |                      |           |                                                        | 50,000 |  |                                                                 | 18,000
|                                                          |                                                                |               |                                                                  |              |  |                                                                                        |         |  |                        |      |                      |           |                                                        |        |  |                                                                 |       
|                                                          |                                                                |               |                                                                  |              |  |                                                                                        |        
|David G. Ludvigson, President and Chief Operating Officer |                                                                | 36,666        |                                                                  |             |  |                                                                                        |        |  |                        | 6.96 |                      | 4/26/2011 |                                                        |       |  |                                                                 |      
|                                                          | 10,000                                                         |               |                                                                 |              |  |                                                                                       |         |  | 8.60                   |      | 6/13/2011            |           |                                                       |        |  |                                                               
|                                                          | 10,000                                                         |               |                                                                 |              |  |                                                                                       |         |  | 2.80                   |      | 6/14/2012            |           |                                                       |        |  |                                                               
|                                                          | 57,970                                                         |               |                                                                 |              |  |                                                                                       |         |  | 3.45                   |      | 7/18/2013            |           |                                                       |        |  |                                                               
|                                                          | 58,822                                                         |               |                                                                 |              |  |                                                                                       |         |  | 3.45                   |      | 7/18/2013            |           |                                                       |        |  |                                                               
|                                                          | 96,015                                                         |               |                                                                 |              |  |                                                                                       |         |  | 3.45                   |      | 7/18/2013            |           |                                                       |        |  |                                                               
|                                                          | 28,985                                                         |               |                                                                 |              |  |                                                                                       |         |  | 3.45                   |      | 7/18/2013            |           |                                                       |        |  |                                                               
|                                                          | 30,210                                                         |               | 15,105                                                           | (4)          |  |                                                                                       |         |  | 6.62                   |      | 6/1/2014             |           |                                                       |        |  |                                                               
|                                                          | 232,290                                                        |               | 22,395                                                           | (4)          |  |                                                                                       |         |  | 6.62                   |      | 6/1/2014             |           |                                                       |        |  |                                                               
|                                                          | 150,000                                                        |               |                                                                 |              |  |                                                                                       |         |  | 4.70                   |      | 7/29/2014            |           |                                                       |        |  |                                                               
|                                                          | 75,000                                                         |               |                                                                 |              |  |                                                                                       |         |  | 4.40                   |      | 7/29/2015            |           |                                                       |        |  |                                                               
|                                                          |                                                               |               |                                                                 |              |  | 155,000                                                                                | (1)     |  | 2.09                   |      | 12/12/2016           |           |                                                       |        |  |                                                               
|                                                          |                                                               |               |                                                                 |              |  | 300,000                                                                                | (2)     |  | 1.39                   |      | 2/16/2017            |           |                                                       |        |  |                                                               
|                                                          |                                                               |               |                                                                 |              |  |                                                                                       |         |  |                       |      |                     |           | 25,000                                                 | (3)    |  | 9,000                                                          
|                                                          |                                                               |               |                                                                 |              |  |                                                                                       |         |  |                       |      |                     |           |                                                       |        |  |                                                               
|                                                          |                                                                |               |                                                                  |              |  |                                                                                        |         |  |                        |      |                      |           |                                                        |        |  |                                                                 |       
|                                                          |                                                                | 785,958       |                                                                  | 37,500       |  |                                                                                        | 455,000 |  |                        |      |                      |           |                                                        | 25,000 |  |                                                                 | 9,000 
|                                                          |                                                                |               |                                                                  |              |  |                                                                                        |         |  |                        |      |                      |           |                                                        |        |  |                                                                 |       



14



---

|                                                                         |                                                                |               |                                                                  |              |     |                                                                                        |         |  |                        |      |                      |           |                                                        |        |  |                                                                 |      
|------------------------------------------------------------------------ | -------------------------------------------------------------- | ------------- | ---------------------------------------------------------------- | ------------ | --- | -------------------------------------------------------------------------------------- | ------- |  | ---------------------- | ---- | -------------------- | --------- | ------------------------------------------------------ | ------ |  | --------------------------------------------------------------- | -----
|Name(7)                                                                  |                                                                | Option Awards |                                                                  | Stock Awards
|                                                                         | Number ofSecuritiesUnderlyingUnexercisedOptions (#)Exercisable |               | Number ofSecuritiesUnderlyingUnexercisedOptions (#)Unexercisable |              |     | EquityIncentivePlan Awards:Number ofSecuritiesUnderlyingUnexercisedUnearnedOptions
(#) |         |  | OptionExercisePrice($) |      | OptionExpirationDate |           | Number ofShares orUnits ofStock ThatHave NotVested (#) |        |  | Market Valueof Shares orUnits of StockThat
HaveNot Vested($)(8)
|(a)                                                                      |                                                                | (b)           |                                                                  | (c)          |     |                                                                                        | (d)     |  |                        | (e)  |                      | (f)       |                                                        | (g)    |  |                                                                 | (h)  
|Robert Saltmarsh, Former Vice President and Chief Financial Officer(6)   |                                                                | 24,841        |                                                                  |             |     |                                                                                        |        |  |                        | 4.33 |                      | 9/13/2014 |                                                        |       |  |                                                                 |     
|                                                                         | 159                                                            |               |                                                                 |              |     |                                                                                       |         |  | 4.33                   |      | 9/13/2014            |           |                                                       |        |  |                                                               
|                                                                         | 78,125                                                         |               | 21,875                                                           | (4)(5)       |     |                                                                                       |         |  | 6.21                   |      | 1/5/2015             |           |                                                       |        |  |                                                               
|                                                                         | 31,250                                                         |               | 18,750                                                           | (4)(5)       |     |                                                                                       |         |  | 6.21                   |      | 1/5/2015             |           |                                                       |        |  |                                                               
|                                                                         | 1,348                                                          |               |                                                                 |              |     |                                                                                       |         |  | 4.40                   |      | 7/29/2005            |           |                                                       |        |  |                                                               
|                                                                         | 36,152                                                         |               |                                                                 |              |     |                                                                                       |         |  | 4.40                   |      | 7/29/2005            |           |                                                       |        |  |                                                               
|                                                                         |                                                               |               |                                                                 |              |     | 95,000                                                                                 | (1)(5)  |  | 2.09                   |      | 12/12/2016           |           |                                                       |        |  |                                                               
|                                                                         |                                                               |               |                                                                 |              |     | 187,500                                                                                | (2)(5)  |  | 1.39                   |      | 2/16/2017            |           |                                                       |        |  |                                                               
|                                                                         |                                                               |               |                                                                 |              |     |                                                                                       |         |  |                       |      |                     |           | 12,500                                                 | (3)(6) |  | 4,500                                                          
|                                                                         |                                                                |               |                                                                  |              |     |                                                                                        |         |  |                        |      |                      |           |                                                        |        |  |                                                                 |      
|                                                                         |                                                                | 171,875       |                                                                  | 40,625       |     |                                                                                        | 282,500 |  |                        |      |                      |           |                                                        | 12,500 |  |                                                                 | 4,500
|                                                                         |                                                                |               |                                                                  |              |     |                                                                                        |         |  |                        |      |                      |           |                                                        |        |  |                                                                 |      
|                                                                         |                                                                |               |                                                                  |              |     |                                                                                        |        
|William L. Respess, Senior Vice President, General Counsel and Secretary |                                                                | 50,369        |                                                                  | 16,666       | (4) |                                                                                        |        |  |                        | 5.87 |                      | 4/30/2014 |                                                        |       |  |                                                                 |     
|                                                                         | 132,965                                                        |               |                                                                 |              |     |                                                                                       |         |  | 5.87                   |      | 4/30/2014            |           |                                                       |        |  |                                                               
|                                                                         | 50,000                                                         |               |                                                                 |              |     |                                                                                       |         |  | 4.70                   |      | 7/29/2014            |           |                                                       |        |  |                                                               
|                                                                         | 982                                                            |               |                                                                 |              |     |                                                                                       |         |  | 4.40                   |      | 7/29/2015            |           |                                                       |        |  |                                                               
|                                                                         | 36,518                                                         |               |                                                                 |              |     |                                                                                       |         |  | 4.40                   |      | 7/29/2015            |           |                                                       |        |  |                                                               
|                                                                         |                                                               |               |                                                                 |              |     | 95,000                                                                                 | (1)     |  | 2.09                   |      | 12/12/2016           |           |                                                       |        |  |                                                               
|                                                                         |                                                               |               |                                                                 |              |     | 187,500                                                                                | (2)     |  | 1.39                   |      | 2/16/2017            |           |                                                       |        |  |                                                               
|                                                                         |                                                               |               |                                                                 |              |     |                                                                                       |         |  |                       |      |                     |           | 12,500                                                 | (3)    |  | 4,500                                                          
|                                                                         |                                                                |               |                                                                  |              |     |                                                                                        |         |  |                        |      |                      |           |                                                        |        |  |                                                                 |      
|                                                                         |                                                                | 270,834       |                                                                  | 16,666       |     |                                                                                        | 282,500 |  |                        |      |                      |           |                                                        | 12,500 |  |                                                                 | 4,500
|                                                                         |                                                                |               |                                                                  |              |     |                                                                                        |         |  |                        |      |                      |           |                                                        |        |  |                                                                 |      
|                                                                         |                                                                |               |                                                                  |              |     |                                                                                        |        
|Graham Lidgard Senior Vice President, Research and Development           |                                                                | 58,139        |                                                                  |             |     |                                                                                        |        |  |                        | 1.72 |                      | 1/14/2013 |                                                        |       |  |                                                                 |     
|                                                                         | 66,861                                                         |               |                                                                 |              |     |                                                                                       |         |  | 1.72                   |      | 1/14/2013            |           |                                                       |        |  |                                                               
|                                                                         | 75,000                                                         |               |                                                                 |              |     |                                                                                       |         |  | 3.45                   |      | 7/18/2013            |           |                                                       |        |  |                                                               
|                                                                         | 25,000                                                         |               |                                                                 |              |     |                                                                                       |         |  | 3.45                   |      | 7/18/2013            |           |                                                       |        |  |                                                               
|                                                                         | 24,201                                                         |               |                                                                 |              |     |                                                                                       |         |  | 4.70                   |      | 7/29/2014            |           |                                                       |        |  |                                                               
|                                                                         | 75,799                                                         |               |                                                                 |              |     |                                                                                       |         |  | 4.70                   |      | 7/29/2014            |           |                                                       |        |  |                                                               
|                                                                         | 10,938                                                         |               |                                                                 |              |     |                                                                                       |         |  | 4.40                   |      | 7/29/2015            |           |                                                       |        |  |                                                               
|                                                                         | 26,562                                                         |               |                                                                 |              |     |                                                                                       |         |  | 4.40                   |      | 7/29/2015            |           |                                                       |        |  |                                                               
|                                                                         |                                                               |               |                                                                 |              |     | 95,000                                                                                 | (1)     |  | 2.09                   |      | 12/12/2016           |           |                                                       |        |  |                                                               
|                                                                         |                                                               |               |                                                                 |              |     | 187,500                                                                                | (2)     |  | 1.36                   |      | 2/16/2017            |           |                                                       |        |  |                                                               
|                                                                         |                                                               |               |                                                                 |              |     |                                                                                       |         |  |                       |      |                     |           | 12,500                                                 | (3)    |  | 4,500                                                          
|                                                                         |                                                                |               |                                                                  |              |     |                                                                                        |         |  |                        |      |                      |           |                                                        |        |  |                                                                 |      
|                                                                         |                                                                | 362,500       |                                                                  |             |     |                                                                                        | 282,500 |  |                        |      |                      |           |                                                        | 12,500 |  |                                                                 | 4,500
|                                                                         |                                                                |               |                                                                  |              |     |                                                                                        |         |  |                        |      |                      |           |                                                        |        |  |                                                                 |      



|(1) | Reflects stock options granted under the Companys 1997 Stock Incentive Plan on December 12, 2006, which become vested only upon the Companys achievement of a
revenue and EBITDA target within five and a half years following the option grant date. In addition, 50% of the option shares will vest on an accelerated basis upon a change in control of the Company and 100% of the option shares will vest on an
accelerated basis upon a change in control of the Company if the change in control price per share is above a target price per share.
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



15



---

|(2) | Reflects stock options which will terminate prior to becoming exercisable unless the Company achieves its goals under the 2007 Executive Officer Incentive Compensation Plan at
predetermined levels. Any options which vested on the basis of the attained levels under the 2007 Executive Officer Incentive Compensation Plan, were subject to a service vesting requirement over a four year period, with twenty-five percent of the
option shares to vest upon the executive officers completion of one year of service following the option grant date, and the remaining option shares to vest monthly over the thirty six month period thereafter. Upon a change in control before
December 31, 2007, 100% of the option shares would become vested and exercisable. In the event of change in control following such date, the outstanding option shares would become vested and exercisable upon the termination of the optionee
under certain circumstances. Based on the Companys performance in 2007, the Compensation Committee determined in February 2008 that 16% of the option shares subject to such option grants remain outstanding: Mr. Birndorf, 21,900 shares;
Mr. Ludvigson, 12,000 shares; Mr. Lidgard, 7,500 shares; Mr. Respess, 7,500 shares.
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(3) | Reflects restricted stock units (RSUs) granted under the Companys 1997 Stock Incentive Plan, which entitle the recipient to one share of our common stock at
the time of vesting without the payment of an exercise price or other consideration. The RSUs become vested in twenty-four equal monthly installments over the two year period commencing on December 12, 2006, provided the executive officer
remains in our employ through each such date. 50% of the vested the shares became issuable on December 12, 2007 and the remaining 50% of the vested shares will become issuable on December 12, 2008, however the RSUs will become vested
on an accelerated basis in the event of the executives involuntary termination within 24 months following a change in control.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(4) | Options vest over a four year period of service with the Company measured from the grant date, with 25% of the option shares vesting after twelve months of service and the balance
vesting monthly thereafter. Each option shall become fully vested and exercisable upon a change in control of the Company. The options held by the named executive officers that vest in accordance with the schedule are as follows:
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|                                                                         |  |                   |  |                               |  |                                                
|------------------------------------------------------------------------ |  | ----------------- |  | ----------------------------- |  | -----------------------------------------------
|Name                                                                     |  | Option Grant Date |  | Total Number of SharesGranted |  | Number of SharesExercised BeforeJanuary 1, 2008
|David G. Ludvigson,                                                      |  | 6/1/2004          |  | 45,315                        |  |                                               
|President and Chief Operating Officer                                    |  | 6/1/2004          |  | 254,685                       |  |                                               
|                                                                         |  |                   | 
|Robert Saltmarsh,                                                        |  | 1/5/2005          |  | 100,000                       |  |                                               
|Former Vice President and Chief Financial Officer                        |  | 1/5/2005          |  | 50,000                        |  |                                               
|                                                                         |  |                   | 
|William L. Respess, Senior Vice President, General Counsel and Secretary |  | 4/30/2004         |  | 67,035                        |  |                                               



|(5) | In connection with his resignation in February 2008, Mr. Saltmarsh forfeited the following unvested shares:
|--- | -----------------------------------------------------------------------------------------------------------



|                |  |                                                 |  |                                                                
|--------------- |  | ----------------------------------------------- |  | ---------------------------------------------------------------
|Expiration Date |  | Number of UnvestedShares as ofDecember 31, 2007 |  | Number of UnvestedShares Mr. SaltmarshForfeited UponTermination
|1/5/2015        |  | 21,875                                          |  | 21,875                                                         
|1/5/2015        |  | 18,750                                          |  | 18,750                                                         
|12/12/2016      |  | 95,000                                          |  | 95,000                                                         
|2/16/2017       |  | 187,500                                         |  | 187,500                                                        



|(6) | In connection with his resignation in February 2008, Mr. Saltmarsh forfeited 10,417 of the 12,500 unvested restricted stock units identified in the table above.
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------

|(7) | Each executive officers outstanding equity awards contain special accelerated vesting provisions, as described under the heading employment, Severance and Change in
Control Agreements.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(8) | Reflects the $0.36 per share closing selling price of the Companys common stock on December 31, 2007.
|--- | ------------------------------------------------------------------------------------------------------



16



---

Option Exercises and Stock Vested

The following table sets forth for each of the named executive officers the number and value of shares of the Corporations common stock subject to
each restricted stock unit award that vested during the year ended December 31, 2007.



|                                                                         |  |                                           |  |                                  
|------------------------------------------------------------------------ |  | ----------------------------------------- |  | ---------------------------------
|                                                                         |  | Stock Awards                             
|Name (a)                                                                 |  | Number of SharesAcquired onVesting (#)(b) |  | Value Realizedon Vesting($)(1)(c)
|Howard Birndorf, Chairman and Chief Executive Officer                    |  | 50,000                                    |  | 20,144                           
|                                                                         |  |                                          
|David G. Ludvigson, President and Chief Operating Officer                |  | 25,000                                    |  | 10,072                           
|                                                                         |  |                                          
|Robert Saltmarsh, Former Vice President and Chief Financial Officer      |  | 12,500                                    |  | 5,036                            
|                                                                         |  |                                          
|William L. Respess, Senior Vice President, General Counsel and Secretary |  | 12,500                                    |  | 5,036                            
|                                                                         |  |                                          
|Graham Lidgard Senior Vice President, Research and Development           |  | 12,500                                    |  | 5,036                            



|(1) | Value realized is determined by multiplying (i) the market price of the common stock on the applicable vesting date by (ii) the number of shares as to which each award
vested on such date.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Pension Benefits

Nanogen does not sponsor a tax-qualified defined benefit retirement plan or a supplemental executive retirement plan.

Nonqualified Deferred Compensation

Nanogen does not sponsor a nonqualified deferred compensation
plan.

Employment, Severance and Change in Control Agreements

The following is a description of the principal provisions of the employment agreements we have entered into with our executive officers.

Howard C. Birndorf

Term.The amended and restated employment agreement we entered into
with Howard C. Birndorf, our chief executive officer, has an initial term three-year ending on January 1, 2010, subject to automatic renewal for one or more successive one-year terms. In the event we elect not to renew the agreement,
Mr. Birndorf may elect to terminate his employment and thereby become entitled to receive salary continuation payments for a period of eighteen months and continued medical coverage for himself and his eligible dependents at our expense for a
period of up to eighteen months.



17



---

Annual Compensation Package. During the term of the employment agreement, Mr. Birndorf will
be entitled to base salary at the rate of $520,150 per year, subject to annual adjustment. He will also be entitled to an annual bonus of up to sixty percent of base salary contingent upon our achievement of performance goals determined by the
Compensation Committee of our board of directors (the Achievement Bonus).

Change in Control Benefits.All stock options
and other equity awards granted to Mr. Birndorf prior to December 12, 2006 will vest in full in the event we experience a change in control. Any stock options or other equity awards subsequently granted to him will be subject to such
accelerated vesting provisions tied to a change in control as our Compensation Committee may establish at the time of such grant. However, each outstanding stock option or other equity award will vest in full automatically upon a change in control
to the extent that option or award is not assumed, continued or replaced by the successor corporation.

The 50,000 restricted stock units
(RSUs) granted to Mr. Birndorf on December 12, 2006 will become vested on an accelerated basis in the event of the executives involuntary termination within 24 months following a change in control.

The option grant for 280,000 shares made to Mr. Birndorf on December 12, 2006 contains special vesting acceleration provisions pursuant to
which the option will automatically vest as to fifty percent of all unvested shares at the time of a change in control and will vest as to all shares if the consideration payable per share of our outstanding common stock in consummation of the
change in control exceeds a certain dollar threshold.

The option grant for 280,000 shares made to Mr. Birndorf on February 16,
2007 contains special vesting acceleration provisions pursuant to which the option will automatically vest as to one hundred percent of the option shares upon a change in control before December 31, 2007. In the event of change in control
following such date, the outstanding option shares would become vested and exercisable upon the termination of the optionee under certain circumstances.

Significant Transaction Benefits.Mr. Birndorf may also receive substantially the same change in control vesting acceleration with respect to his pre-December 12, 2006 stock options and equity awards
upon the occurrence of a significant transaction effecting a change in ownership (other than a change in control) which results, in the judgment of our board of directors, in significant additional value for our stockholders, such as the addition of
a major new investor group or the formation of a significant joint venture. In addition, upon the occurrence of such a significant event, Mr. Birndorf may become entitled to a special cash transaction bonus equal to one hundred and eighty
percent of his then-current rate of annual base salary (the Transaction Bonus). The Transaction Bonus will be in lieu of any Achievement Bonus for the year for which it is paid. Any such significant transaction benefits will be payable
solely in the discretion of our board of directors.

Change in Control Severance Benefits.If Mr. Birndorfs employment is
terminated by us without cause, or if he resigns by reason of a material reduction in his duties, authority and responsibilities, within twenty-four months following a change in control transaction, provided he executes a general release of claims
against the company, he will become entitled to the following payments and benefits:

(i) salary continuation payments for a period of
twenty-four months;

(ii) a pro-rated Achievement Bonus payable in a lump sum, whether or not the performance objectives for the year are
attained;

(iii) accelerated vesting of all outstanding unvested stock options and other equity awards; and

(iv) continued medical coverage for Mr. Birndorf and his eligible dependents at our expense for up to an eighteen-month period.



18



---

Limited Tax Gross-Up.Stock options and other equity awards granted to Mr. Birndorf under our
1997 Stock Incentive Plan (the Plan) prior to December 12, 2006 contain a special tax gross-up provision. Accordingly, if the aggregate amount of all payments or benefits provided Mr. Birndorf under his employment agreement
with us and any other plans or agreements he may have with us would subject him to the excise tax imposed by Section 4999 of the Internal Revenue Code, then he will be entitled to receive a special tax payment from us in an amount sufficient to
cover the portion of that excise tax, together with interest and penalties, allocable to the pre-December 12, 2006 stock options and equity awards granted to him under the Plan, plus all income and employment taxes and additional excise taxes
on that tax payment.

Normal Severance.Should Mr. Birndorfs employment be terminated by us without cause, or should he
resign by reason of a material reduction in his powers, duties and responsibilities, either before the occurrence of a change in control transaction or more than twenty-four months following a change in control transaction, then he will become
entitled to salary continuation payments for a period of eighteen months and continued medical coverage for himself and his eligible dependents at our expense for a period of up to eighteen months.

Other Executive Officers

The employment
agreements with each of our other executive officers, namely, Messrs. Ludvigson, Lidgard, Respess, Venuto and Saltmarsh are substantially the same except as to the rate of their individual base salary and target bonus and may be summarized as
follows:

Term.The amended and restated employment agreement we entered into with each of our other executive officers has an
initial three-year term ending on January 1, 2010, subject to automatic renewal for one or more successive one-year terms. In the event we elect not to renew the agreement, the executive officer may elect to terminate his employment and thereby
become entitled to receive salary continuation payments for a period of six months.

Annual Compensation Package. The annual rate of
base salary and target bonus as a percentage of that salary is as follows for each of the executive officers:



|             |  |             |         |              |   |        
|------------ |  | ----------- | ------- | ------------ | - | -------
|Name         |  | Base Salary |         | Target Bonus
|D. Ludvigson |  | $           | 360,500 |              | $ | 180,250
|G. Lidgard   |  | $           | 290,460 |              | $ | 116,184
|L. Respess   |  | $           | 329,600 |              | $ | 131,840
|R. Saltmarsh |  | $           | 257,500 |              | $ | 103,000
|N. Venuto    |  | $           | 220,000 |              | $ | 77,000 

Payment of the target bonus will be contingent upon our achievement of performance goals
determined annually by the Compensation Committee of our board of directors (the Achievement Bonus).

Change in Control
Benefits.In the event we experience a change in control, each executive officer will be entitled to the same change in control vesting acceleration benefits described above for Mr. Birndorf. In addition, as with Mr. Birndorf:



| |  |  | The option grants made to the executive officers on December 12, 2006 contain special vesting acceleration provisions pursuant to which the option will
automatically vest as to fifty percent of all unvested shares at the time of a change in control and will vest as to all shares if the consideration payable per share of our outstanding common stock in consummation of the change in control exceeds a
certain dollar threshold.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | The restricted stock unit awards made to the executive officers on December 12, 2006 will become vested on an accelerated basis in the event of the
executives involuntary termination within 24 months following a change in control.
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



19



---

| |  |  | The option grants made to the executive officers on February 16, 2007 contains special vesting acceleration provisions pursuant to which the option will
automatically vest as to one hundred percent of the option shares upon a change in control before December 31, 2007. In the event of change in control following such date, the outstanding option shares would become vested and exercisable upon
the termination of the optionee under certain circumstances.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Significant Transaction Benefits.As is the case
with Mr. Birndorf, each executive officer (except for Mr. Venuto) may also receive (i) the same change in control vesting acceleration benefits described above and (ii) a transaction bonus of fifty percent (one hundred percent
for Mr. Ludvigson) of the executive officers then-current rate of annual base salary upon the occurrence of a significant transaction effecting a change in ownership (other than a change in control) which results, in the judgment of our
board of directors, in significant additional value for our stockholders. Any such Transaction Bonus will be in lieu of any Achievement Bonus for the year for which it is paid. However, any such significant transaction benefits will be payable
solely in the discretion of our board of directors.

Change in Control Severance Benefits.If the executive officers
employment is terminated by us without cause, or if he resigns by reason of a material reduction in his powers, duties and responsibilities, within twenty-four months following a change in control transaction, provided he executes a general release
of all claims against the Company, he will become entitled to the following payments and benefits:

(i) salary continuation payments for a
period of twelve months (eighteen months for Mr. Ludvigson);

(ii) a pro-rated Achievement Bonus payable in a lump sum, whether or not
the performance objectives for the year are attained;

(iii) accelerated vesting of all outstanding unvested stock options and other equity
awards; and

(iv) continued medical coverage for the executive officer and his eligible dependents at our expense for up to a twelve-month
period (eighteen months for Mr. Ludvigson).

Limited Tax Gross-Up.Stock options and other equity awards granted to the
executive officer under our 1997 Stock Incentive Plan (the Plan) prior to December 12, 2006 contain a special tax gross-up provision. Accordingly, if the aggregate amount of all payments or benefits provided the executive officer
under his employment agreement with us and any other plans or agreements he may have with us would subject him to the excise tax imposed by Section 4999 of the Internal Revenue Code, then he will be entitled to receive a special tax payment
from us in an amount sufficient to cover the portion of that excise tax, together with interest and penalties, allocable to the pre-December 12, 2006 stock options and equity awards granted to him under the Plan, plus all income and employment
taxes and additional excise taxes on that tax payment.

Normal Severance.Should the executive officers employment be
terminated by us without cause, or should he resign by reason of a material reduction in his authority, duties and responsibilities, either before the occurrence of a change in control transaction or more than twenty-four months following a change
in control transaction, then he will become entitled to salary continuation payments for a period of six months and continued medical coverage for himself and his eligible dependents at our expense or a period of up to six months. In addition, upon
a termination not associated with a change in control, 50% of Mr. Respess unvested equity awards will become vested on an accelerated basis.

Post-termination Exercise of Stock Options. Stock options granted to Mr. Respess which are vested at the time of his termination of employment for any reason will remain outstanding until the 10 year
anniversary of the grant date of each such option, unless exercised by Mr. Respess prior to such date.



20



---

Quantification of Benefits

The charts below indicate the potential payments each of our executive officers would receive based upon the following assumptions:

(i) his employment terminated on December 31, 2007 under circumstances entitling him to severance benefits under his employment agreement,

(ii) as to any benefits tied to the executives rate of base salary, the rate of base salary is assumed to be the executives rate of base
salary as of December 31, 2007,

(iii) as to any benefits tied to a change in control, the change in control is assumed to have
occurred on December 31, 2007 and the change in control consideration paid per share of outstanding common stock is assumed to be equal to the closing selling price of our common stock on December 31, 2007, which was $0.36 per share, and

(iv) as to any benefits tied to a significant transaction, the significant transaction is assumed to occur on December 31, 2007 and
our board of directors exercised its discretion to pay the maximum amount of significant transaction benefits payable under the employment agreement.

In February 2008, our Chief Financial Officer, Robert Saltmarsh, announced his retirement. Mr. Saltmarsh was not entitled to any severance benefits in connection with his resignation.

BENEFITS RECEIVED UPON TERMINATION IN CONNECTION WITH A CHANGE IN CONTROL



|                |  |                        |  |                      |  |                          |  |          
|--------------- |  | ---------------------- |  | -------------------- |  | ------------------------ |  | ---------
|Executive       |  | SalaryContinuation ($) |  | AchievementBonus ($) |  | AcceleratedEquity ($)(1) |  | COBRA ($)
|Howard Birndorf |  | 1,040,300              |  | 312,090              |  | 18,000                   |  | 23,112   
|David Ludvigson |  | 540,750                |  | 180,250              |  | 9,000                    |  | 37,356   
|Graham Lidgard  |  | 290,460                |  | 116,184              |  | 4,500                    |  | 18,129   
|Larry Respess   |  | 329,600                |  | 131,840              |  | 4,500                    |  | 18,129   



|(1) | Represents the intrinsic value of each stock option or other equity award which vests on an accelerated basis in connection with the change in control or termination of employment
and is calculated by multiplying (i) the aggregate number of equity awards which vest on such an accelerated basis by (ii) the amount by which the $0.36 closing selling price of our common stock on December 31, 2007 exceeds any
exercise price payable per vested share.
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Based on the $0.36 closing selling price of our common stock on December 31,
2007, the Company believes that no limited tax gross-up payment would have been made in connection with a change in control on December 31, 2007.

POTENTIAL BENEFITS PAYABLE IN CONNECTION WITH A SIGNIFICANT TRANSACTION



|                |  |                         |  |                         
|--------------- |  | ----------------------- |  | ------------------------
|Executive       |  | TransactionBonus ($)(1) |  | AcceleratedEquity ($)(2)
|Howard Birndorf |  | 936,270                 |  | 18,000                  
|David Ludvigson |  | 360,500                 |  | 9,000                   
|Graham Lidgard  |  | 145,230                 |  | 4,500                   
|Larry Respess   |  | 164,800                 |  | 4,500                   



|(1) | Represents the maximum transaction bonus payable. If a significant transaction had actually occurred at the Companys stock price of $0.36 on December 31, 2007, no
transaction bonus would have been payable to the named executive officers.
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



21



---

|(2) | Represents the intrinsic value of each pre-December 2006 stock option or other equity award which could potentially vest on an accelerated basis in connection with the significant
transaction, and is calculated by multiplying (i) the aggregate number of pre-December 2006 equity awards which vest on such an accelerated basis by (ii) the amount by which the $0.36 closing selling price of our common stock on
December 31, 2007 exceeds any exercise price payable per vested share.
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BENEFITS RECEIVED UPON
TERMINATION NOT IN CONNECTION WITH A CHANGE IN CONTROL



|                |  |                       |  |         
|--------------- |  | --------------------- |  | --------
|Executive       |  | SalaryContinuation($) |  | COBRA($)
|Howard Birndorf |  | 780,225               |  | 23,112  
|David Ludvigson |  | 180,250               |  | 12,453  
|Graham Lidgard  |  | 145,230               |  | 9,064   
|Larry Respess   |  | 164,800               |  | 9,064   

Compensation of Directors

The following table sets forth certain information regarding the compensation earned by or awarded to each non-employee director during the 2007 Fiscal Year who served on our Board of Directors in the 2007 Fiscal
Year. The Company does not sponsor a non-equity incentive plan, a pension plan, or a non-qualified deferred compensation plan for its non-employee directors.



|                        |  |                                  |  |                    |  |                        |     |  |                          |     |  |         
|----------------------- |  | -------------------------------- |  | ------------------ |  | ---------------------- | --- |  | ------------------------ | --- |  | --------
|Name                    |  | Fees Earned orPaid in Cash($)(1) |  | Stock Awards($)(2) |  | Option Awards($)(3)(4) |     |  | All OtherCompensation($) |     |  | Total($)
|(a)                     |  | (b)                              |  | (c)                |  | (d)                    |     |  | (e)                      |     |  | (f)     
|Heiner Dreismann        |  | 8,241                            |  | 25,000             |  | 8,987                  | (5) |  | 60,000                   | (6) |  | 102,228 
|Stelios B. Papadopoulos |  | 28,000                           |  | 25,000             |  |                       |     |  |                         |     |  | 53,000  
|David Schreiber         |  | 21,982                           |  | 25,000             |  |                       |     |  |                         |     |  | 46,982  
|Robert E. Whalen        |  | 20,232                           |  | 25,000             |  |                       |     |  |                         |     |  | 45,232  



|(1) | Consists of the meeting fees for service as members of the Companys board of directors. For further information concerning such fees, see the section below entitled
Director Annual Retainer and Meeting Fees.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(2) | The amounts in column (c) reflect the dollar amount recognized for financial statement reporting purposes for the fiscal year ended December 31, 2007, in accordance with
FAS 123(R) of stock awards granted to each non-employee director as a retainer fee in the 2007 year. The grant date fair value of each annual retainer fee equity award granted during the 2007 fiscal year, computed in accordance with FAS 123(R), was
$25,000. The number of shares subject to such retainer fee award in 2007 was 18,116 shares. For further information concerning such fees, see the section below entitled Director Annual Retainer and Meeting Fees.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(3) | The amounts in column (d) do not reflect actual proceeds received, but rather these amounts reflect the dollar amount recognized for financial statement reporting purposes for
the fiscal year ended December 31, 2007, in accordance with FAS 123(R) of stock options granted to each non-employee director and thus include amounts from awards granted in and prior to the 2007 year. Assumptions used in the calculation of
this amount are included in footnote 8 to the Companys audited financial statements for the fiscal year ended December 31, 2007 included in the Companys Annual Report on Form 10-K filed with the Securities and Exchange Commission on
March 31, 2008.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(4) | As of December 31, 2007 the following non-employee directors held options to purchase the following number of shares of the Companys common stock: Dr. Dreismann,
25,000 shares; Mr. Papadopoulos, 55,000 shares; Mr. Schreiber, 25,000 shares; and Mr. Whalen, 25,000 shares. The following table shows the grant date, exercise price and number of shares outstanding for each outstanding option held by
a non-employee director.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



22



---

|                 |  |            |  |                |       |                                    |       
|---------------- |  | ---------- |  | -------------- | ----- | ---------------------------------- | ------
|Name             |  | Grant Date |  | Exercise Price |       | Number of Option SharesOutstanding
|Dr. Dreismann    |  | 10/27/06   |  | $              | 1.95  |                                    | 25,000
|Mr. Papadopoulos |  | 10/29/99   |  | $              | 7.00  |                                    | 25,000
|Mr. Papadopoulos |  | 6/6/00     |  | $              | 35.00 |                                    | 10,000
|Mr. Papadopoulos |  | 6/13/01    |  | $              | 8.60  |                                    | 10,000
|Mr. Papadopoulos |  | 6/14/02    |  | $              | 2.80  |                                    | 10,000
|Mr. Schreiber    |  | 6/12/03    |  | $              | 4.07  |                                    | 25,000
|Mr. Whalen       |  | 4/26/02    |  | $              | 3.50  |                                    | 25,000



|(5) | Represents the dollar amount recognized for financial statement reporting purposes for the fiscal year ended December 31, 2007, in accordance with FAS 123(R), with respect to
the 25,000 share option granted to Dr. Dreismann under our 1997 Stock Incentive Plan upon Mr. Dreismanns election to the board, the terms of which are described in more detail below under the heading 1997 Stock Incentive
Plan.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(6) | Represents the aggregate amount of consulting fees paid by us in 2007 under our consulting agreement with Dr. Dreismann, the terms of which are described in more detail below
under the heading HeinerDreismann, Ph.D. Consulting Agreement.
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Directors Annual Retainer and
Meeting Fees

Each non-employee Board member receives an annual retainer of $25,000 to be paid entirely in shares of our Common Stock,
based on the closing stock price on the date of the Companys Annual Meeting of Stockholders. These shares are issued under our 1997 Stock Incentive Plan. Accordingly, on June 13, 2007, Messrs. Whalen, Papadopoulos, Schreiber and Dreismann
each received 18,116 shares of our Common Stock. In addition, each non-employee Board member receives an annual retainer of $1,500, to be paid entirely in cash, for each Board committee on which he or she serves and the Chairman of the Audit and
Compensation Committees receive an additional annual cash retainer of $10,000 and $2,500, respectively, for their service on such committees. Non-employee Board members also receive the following additional cash payments: $2,000 per Board meeting
attended ($750 per Board meeting participated in by phone) and $750 per Board committee meeting attended or participated in by phone.

1997 Stock Incentive Plan.

Pursuant to the 1997 Stock Incentive Plan, each non-employee Board member may elect to convert
all or part of his or her annual cash retainer payments and/or meeting fees from us in the form of non-qualified stock options, restricted stock, stock units, or a combination thereof. In 2007, none of our non-employee Board members elected to
convert their annual cash retainer payments and cash meeting fees into stock options, restricted stock or restricted stock units.

Upon
initial appointment or election to the Board, a non-employee director will receive an option grant under our 1997 Stock Incentive Plan to purchase 25,000 shares of the our Common Stock at an exercise price equal to the fair market value of the
option shares on the grant date. These options vest at a rate of 25% after one year and the remainder ratably over the remaining three years. The vesting of the option shares will accelerate if there is a Change of Control as defined in the plan.
Accordingly, on October 27, 2006 Mr. Dreismann received an option to purchase 25,000 shares of our Common Stock at an exercise price per share of $1.95, the fair market value of our Common Stock on such date.

In the event any payment or benefit provided under the Companys 1997 Stock Incentive Plan to any Board member would subject that individual to the
excise tax imposed by Section 4999 of the Internal Revenue Code relating to excess parachute payments, then such individual will be entitled to receive an additional payment from us in an amount equal to the amount of the excise tax
imposed on such payment or benefit, together with any interest and penalties (a Gross-Up Payment) plus the income taxes and additional excise tax, together with any interest and penalties, imposed on the Gross-Up Payment.



23



---

Heiner Dreismann, Ph.D. Consulting Agreement

On October 1, 2006, the Company entered into an Independent Contractor Agreement for Consulting Services (the Consulting Agreement) with
Dr. Dreismann, pursuant to which Dr. Dreismann agreed to provide certain technical consulting services on molecular diagnostic products and markets for the Company. In consideration for such services, the Company agreed to pay
Dr. Dreismann a fee of $10,000 for the month of October, 2006 and $5,000 each month thereafter, provided that the total amount of payment to Dr. Dreismann under the Consulting Agreement shall not exceed $60,000 per year without written
approval by the Company.

Compensation Committee Interlocks and Insider Participation

The following individuals served as members of our Compensation Committee during fiscal year 2006: David Schreiber and Robert Whalen, each of whom was an
independent director during fiscal year 2006. During 2006, none of our officers or employees served on the compensation committee (or equivalent) or the board of directors of another entity whose executive officer(s) served on our Compensation
Committee or Board.

Securities Authorized for Issuance under Equity Compensation Plans

The following table provides information with respect to the shares of our Common Stock that may be issued under our existing equity compensation plans as
of December 31, 2007. The table excludes information related to the outstanding options granted under our equity compensation plans where no additional options may be granted. Footnote 7 to the table sets forth the total number of shares and
weight average of the exercise price of the shares excluded from this table.

Plan Category



|                                                          |  |                                                                                     |     |  |                                                                         |      |     |                                                                                                 |           |    
|--------------------------------------------------------- |  | ----------------------------------------------------------------------------------- | --- |  | ----------------------------------------------------------------------- | ---- | --- | ----------------------------------------------------------------------------------------------- | --------- | ---
|                                                          |  | A.Number ofShares to
beIssued UponExercise ofOutstandingOptions, Warrants andRights |     |  | B.WeightedAverageExercisePrice ofOutstandingOptions, Warrants andRights |      |     | C.Number ofSharesRemainingAvailable forFuture Issuance(ExcludingSecuritiesReflected InColumn A) |          
|Equity compensation plans approved by stockholders(1)     |  | 8,639,521                                                                           | (2) |  | $                                                                       | 3.51 | (3) |                                                                                                 | 3,207,263 | (4)
|Equity compensation plans not approved by stockholders(5) |  | 1,668,040                                                                           |     |  | $                                                                       | 2.54 |     |                                                                                                 | 728,044   | (6)
|                                                          |  |                                                                                     |     |  |                                                                         |      |     |                                                                                                 |           |    
|Total                                                     |  | 10,307,561                                                                          |     |  | $                                                                       | 3.35 |     |                                                                                                 | 3,935,307 |    
|                                                          |  |                                                                                     |     |  |                                                                         |      |     |                                                                                                 |           |    



|(1) | Consists of the Nanogen, Inc. 1998 Employee Stock Purchase Plan (the Purchase Plan), the Nanogen, Inc. Stock Bonus Plan (the Bonus Plan) and our three stock
option plans: the 1993 Stock Option Plan, the 1995 Stock Option/Stock Issuance Plan and the 1997 Stock Incentive Plan.
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(2) | Includes 195,000 shares or our common stock subject to RSUs that will entitle each holder to one share of our common stock for each unit that vest over the holders
period of continued service. Excludes purchase rights accruing under the Employee Stock Purchase Plan which has a shareholder approved reserve of 1,600,000 shares. Under the Employee Stock Purchase Plan, each eligible employee may purchase up to
1,666 shares of Common Stock at semi-annual intervals on the last business day of June and December each year at a purchase price per share equal to 85% of the lower of (i) the closing selling price per share of Common Stock on the last trading
day preceding the offering period in which that semi-annual purchase date occurs, or (ii) the closing selling price per share on the semi-annual purchase date.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(3) | Calculated without taking into account 195,000 shares of our common stock subject to outstanding RSUs that will become issuable as those units vest, without any cash
consideration or other payment required for such shares.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



24



---

|(4) | Consists of shares available for issuance under the Bonus Plan, the 1998 Employee Stock Purchase Plan, and the 1997 Stock Incentive Plan. As of December 31, 2007, 178,390
shares were available for issuance under the Bonus Plan 195,595 and 2,833,278 shares were available for issuance under the 1998 Employee Stock Purchase Plan, and 1997 Stock Incentive Plan, respectively. The 2,833,278 shares available for issuance
under the 1997 Stock Plan may be issued upon the exercise of stock options or stock appreciation rights granted under the plan or those shares may be issued pursuant to direct stock bonuses or restricted stock issuances, restricted stock units or
other share right awards which vest upon the attainment of prescribed performance milestones or the completion of designated service periods. The 178,390 shares available under the Bonus Plan may be issued through direct stock bonuses or pursuant to
restricted stock or restricted stock unit awards which vest upon the attainment of prescribed performance milestones or the completion of designated service periods.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(5) | Consists of the Epoch Biosciences, Inc. 2003 Stock Incentive Plan. In connection with the acquisition of Epoch Biosciences, Inc., in December 2004, we assumed options to purchase
923,920 shares of Epoch Biosciences, Inc. common stock under the Epoch Biosciences, Inc. 2003 Stock Incentive Plan and converted them into options to purchase 0.4673 shares of Common Stock in accordance with the exchange ratio in effect for that
acquisition. The 728,044 shares available for issuance under Epoch Biosciences, Inc. 2003 Stock Incentive Plan, as of December 31, 2007, may be issued upon the exercise of stock options or stock appreciation rights granted under the plan or
those shares may be issued pursuant to direct stock bonuses or restricted stock issuances, restricted stock units or other share right awards which vest upon the attainment of prescribed performance milestones or the completion of designated service
periods.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(6) | The Epoch Biosciences, Inc. 2003 Stock Incentive Plan contains a provision whereby the share reserve under the plan will automatically increase on the first business day of January
each year that the plan remains in existence. The increase to the share reserve under the plan will be limited each year to 350,475 shares or such lesser number of shares as may be determined by the board. Any annual increase will be reduced to the
extent necessary to ensure that the number of shares available under the plan (the shares subject to outstanding options plus the remaining unallocated shares available under the plan) does not at the time exceed 2,715,718 shares of our common
stock. On January 1, 2007 the number of shares of Common Stock available for issuance under the assumed Epoch Biosciences, Inc. 2003 Stock Incentive Plan increased by 350,475 shares pursuant to the automatic share increase provisions of that
plan.
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(7) | The table does not include information with respect to outstanding options granted under certain equity compensation plans assumed by us in connection with mergers and acquisitions
and which no additional options may be granted. As of December 31, 2007 a total of 680,612 shares of Common Stock were subject to those assumed options, and the weighted average exercise price of those assumed options was $10.14 per share.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The Epoch Biosciences, Inc. 2003 Stock Incentive Plan

As of December 16, 2004, approximately 431,760 shares of Common Stock had been reserved for issuance under the Epoch Biosciences, Inc. 2003 Stock
Incentive Plan (as assumed by the Company) to eligible individuals in our service or the service of our subsidiaries. Such eligible individuals include (i) employees, directors and officers of Epoch Biosciences, Inc or its subsidiaries whose
service commenced prior to the December 16, 2004 date of the acquisition and (ii) employees, directors and executive officers of Nanogen or its subsidiaries (including Epoch Biosciences, Inc.) whose service commenced or commences after
December 16, 2004. Awards under the assumed Epoch Biosciences, Inc. 2003 Stock Incentive Plan may be in the form of non-statutory stock option grants with an exercise price of not less than 100% of the fair market value of the Common Stock on
the grant date, stock bonuses for services rendered, or stock issuances with a purchase price not less than 100% of the fair market value of the Common Stock on the award date. No option grants will have a maximum term in excess of 10 years, and
each option grant or direct stock issuance will generally vest over one or more years of service. However, upon certain changes in control or ownership, those options and stock issuances may vest in whole or in part on an accelerated basis. On
January 1, 2007, 2006 and 2005 the number of shares of Common Stock available for issuance under the assumed Epoch Biosciences, Inc. 2003 Stock Incentive Plan increased by 350,475 shares pursuant to the automatic share increase provisions of
that plan. As of December 31, 2007 options to purchase 1,668,040 shares of Common Stock were outstanding under the assumed Epoch Biosciences, Inc. 2003 Stock Incentive Plan, 2,396,084 shares of Common Stock had been authorized under such plan,
and 728,044 shares of Common Stock remained available for future issuance.



25



---

COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION

The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis contained in this proxy statement with management, and
based on such review and such discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis, as contained herein, be included in this Proxy Statement.

Compensation Committee

David Schreiber, Chairman

Robert Whalen

AUDIT COMMITTEE REPORT

The following
is the report of the Audit Committee with respect to Nanogens audited financial statements for the year ended December 31, 2007.

The purpose of the Audit Committee is to assist the Board in its general oversight of Nanogens financial reporting, internal controls and audit functions. The Audit Committee is comprised solely of independent directors as defined by
the listing standards of Nasdaq Stock Market, Inc.

The Audit Committee has reviewed and discussed the consolidated financial statements
with management and Ernst & Young LLP, the Companys independent registered public accounting firm. Management is responsible for the preparation, presentation and integrity of Nanogens financial statements; accounting and
financial reporting principles; establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)); establishing and maintaining internal control over financial reporting (as defined in Exchange Act Rule
13a-15(f)); evaluating the effectiveness of disclosure controls and procedures; evaluating the effectiveness of internal control over financial reporting; and evaluating any change in internal control over financial reporting that has materially
affected, or is reasonably likely to materially affect, internal control over financial reporting. Ernst & Young LLP is responsible for performing an independent audit of the consolidated financial statements and expressing an opinion on
the conformity of those financial statements with accounting principles generally accepted in the United States of America, as well as expressing an opinion the effectiveness of internal control over financial reporting.

During fiscal year 2007, the Audit Committee reviewed, discussed and provided input on the Companys audited consolidated financial statements
contained in the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2007. The Audit Committee also met regularly with Ernst & Young LLP to evaluate and approve the Companys internal controls and the
overall quality of the Companys financial reporting. The Audit Committee also met with the Companys Chief Executive Officer and Chief Financial Officer to discuss and act, as necessary, on accounting issues. The Audit Committee also
reviewed the report of management contained in the Companys Annual Report on Form 10-K for the year ended December 31, 2007 filed with the SEC, as well as Ernst & Young LLPs Report of Independent Registered Public
Accounting Firm included in the Companys Annual Report on Form 10-K.

The Audit Committee continues to oversee the Companys
efforts related to its internal control over financial reporting and managements preparations for the evaluation in 2008.

The Audit
Committee has discussed with Ernst & Young LLP the matters required to be discussed by Statement on Auditing Standards No. 61, as amended, Communication with Audit Committees and PCAOB Auditing Standard No. 2, An
Audit of Internal Control Over Financial Reporting Performed in Conjunction with an Audit of Financial Statements. In addition, Ernst & Young LLP has provided the Audit Committee with the written disclosures and the letter required by
the Independence Standards Board Standard No. 1, as amended,



26



---

Independence Discussions with Audit Committees, and the Audit Committee has discussed with Ernst & Young LLP their firms
independence.

Based on their review of the consolidated financial statements and discussions with and representations from management and
Ernst & Young LLP referred to above, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in Nanogens Annual Report on Form 10-K for the fiscal year ended December 31, 2007,
for filing with the Securities and Exchange Commission.

Audit Committee

Stelios B. Papadopoulos, Chairman

David Schreiber

Robert E. Whalen



|Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
|-------- | ----------------------------------------------------------------------------------------------

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS,

DIRECTORS AND MANAGEMENT

The following table sets forth information as of April 7, 2008
(except as noted below) as to our shares of Common Stock beneficially owned by (i) each of our directors, (ii) each of our executive officers in the Summary Compensation Table set forth herein, (iii) our current directors and
executive officers as a group and (iv) each person known by us to be the beneficial owner of more than 5% of the outstanding shares of our Common Stock. Unless otherwise indicated, the beneficial ownership consists of sole voting and investment
power with respect to the shares indicated, except to the extent that a spouse shares authority under applicable law. Except for shares of common stock held in brokerage accounts, which may, from time to time together with other securities in the
account, serve as collateral for margin loans made in such accounts, none of the shares reported as beneficially owned have been pledged as security for any loan or indebtedness.



|                                                                |                 |                                        |                    |     |  
|--------------------------------------------------------------- | --------------- | -------------------------------------- | ------------------ | --- | -
|                                                                |                 | Beneficial Ownership ofCommon Stock(1) |                   
|                                                                | Number ofShares |                                        | Percentageof Class |    
|Fisher Scientific International, Inc.(2)                        |                 | 5,660,377                              |                    | 7.7 | %
|Liberty Lane                                                    |                 |                                        |                    |     |  
|Hampton, NH 03842                                               |                 |                                        |                    |     |  
|Howard C. Birndorf(3)                                           |                 | 2,215,552                              |                    | 3.0 | %
|c/o Nanogen, Inc.                                               |                 |                                        |                    |     |  
|10398 Pacific Center Court                                      |                 |                                        |                    |     |  
|San Diego, CA 92121                                             |                 |                                        |                    |     |  
|David G. Ludvigson(4)                                           |                 | 911,213                                |                    | 1.0 | %
|Robert Saltmarsh(5)                                             |                 | 237,102                                |                    | *   |  
|Graham Lidgard(6)                                               |                 | 408,705                                |                    | *   |  
|William L. Respess(7)                                           |                 | 375,641                                |                    | *   |  
|Robert Whalen(8)                                                |                 | 74,399                                 |                    | *   |  
|Stelios Papadopoulos(9)                                         |                 | 104,399                                |                    | *   |  
|David Schreiber(10)                                             |                 | 70,399                                 |                    | *   |  
|Heiner Dreisman(11)                                             |                 | 36,124                                 |                    | *   |  
|All directors and executive officers as a group (9 persons)(12) |                 | 4,286,039                              |                    | 5.8 | %



27



---



|* | Less than one percent.
|- | ----------------------

|(1) | Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission (the SEC), based on factors including voting and investment
power with respect to shares. Percentage of beneficial ownership is based on the number of shares of the Companys common stock outstanding as of April 7, 2008. Shares of common stock issuable upon exercise of options currently
exercisable, or exercisable within 60 days as of April 7, 2008 and shares of common stock issuable within 60 days as of April 7, 2008 pursuant to outstanding restricted stock units, are deemed outstanding for purpose of computing the
percentage ownership of the person holding such options or restricted stock units, but are not deemed outstanding for computing the percentage ownership of any other person.
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(2) | Pursuant to a Schedule 13G filed on March 15, 2006 with the SEC, Fisher Scientific International, Inc. had sole power to vote or to direct the vote of 5,660,377 shares of
common stock and had sole power to dispose or to direct the disposition of 5,660,377 shares of common stock. The address of principal business office of Fisher Scientific International, Inc, is Liberty Lane, Hampton, NH 03842.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(3) | Includes 1,500,000 shares issuable upon the exercise of option within 60 days of April 7, 2008.
|--- | -----------------------------------------------------------------------------------------------

|(4) | Includes 823,458 shares issuable upon the exercise of options within 60 days of April 7, 2008.
|--- | ----------------------------------------------------------------------------------------------

|(5) | Includes 178,125 shares issuable upon the exercise of options within 60 days of April 7, 2008.
|--- | ----------------------------------------------------------------------------------------------

|(6) | Includes 362,500 shares issuable upon the exercise of options within 60 days of April 7, 2008.
|--- | ----------------------------------------------------------------------------------------------

|(7) | Includes 287,500 shares issuable upon the exercise of options within 60 days of April 7, 2008.
|--- | ----------------------------------------------------------------------------------------------

|(8) | Includes 25,000 shares issuable upon the exercise of options within 60 days of April 7, 2008.
|--- | ---------------------------------------------------------------------------------------------

|(9) | Includes 55,000 shares issuable upon the exercise of options within 60 days of April 7, 2008.
|--- | ---------------------------------------------------------------------------------------------

|(10) | Includes 25,000 shares issuable upon the exercise of options within 60 days of April 7, 2008.
|---- | ---------------------------------------------------------------------------------------------

|(11) | Includes 9,895 shares issuable upon the exercise of options within 60 days of April 7, 2008.
|---- | --------------------------------------------------------------------------------------------

|(12) | Includes five (5) Board members, one of whom is an executive officer, and four (4) other current executive officers.
|---- | --------------------------------------------------------------------------------------------------------------------



|Item 13. | Certain Relationships and Related Transactions and Director Independence
|-------- | ------------------------------------------------------------------------

CERTAIN TRANSACTIONS

In June 2005, we signed a letter of agreement with
FasTraQ, Inc. (FasTraQ) for the development of a certain future product. Our Chief Executive Officer and Chairman of the Board, Mr. Birndorf, is a director and an investor in FasTraQ and our newest director, Dr. Heiner
Dreismann, became CEO of FasTraQ in 2006. In October and December 2005 we amended this letter of agreement. As a result of this agreement and related amendments we made an initial non-refundable payment of $500,000 in 2005 to begin the initial
development of this product. As of December 31, 2005, we expensed the initial $500,000. In February 2006, we converted this letter of agreement into two executed contracts, a Development and License Agreement and a Collaboration Agreement. In
February 2006, we committed to provide FasTraQ up to an additional $500,000 in funding based on certain milestones, of which $200,000 was paid in 2006 and expensed into research and development. In February 2007, the companies terminated these
agreements by mutual agreement. There were no additional funds provided to FasTraQ during 2007.

In October 2006, we signed a consulting
agreement with Mr. Dreismann, one of our Board members, and the agreement was amended in November 2006, and again in September 2007. Mr. Dreismann received $60,000 and $20,000 in compensation under this agreement during 2007 and 2006,
respectively. Total compensation under the agreement is capped at a maximum of $5,000 per month.

On August 3, 2006, we entered into
research and development collaboration arrangements with Fisher Scientific International Inc., (Fisher Scientific) a related party, that owns approximately 5.7 million shares of our common stock, and Athena Diagnostic, a
wholly-owned subsidiary of Fisher Scientific. We agreed to share certain technology and patent rights related to the development, manufacture and marketing of new molecular diagnostic products. Under these arrangements, Fisher Scientific has the
option to provide up to $10 million in



28



---

2007 and 2008 for the research and development of infectious disease and molecular diagnostic tests that will be mutually agreed upon. These arrangements are
included in non-binding general agreements, thus the obligation of the parties are subject to further negotiation and final terms of definitive collaboration agreements. On August 9, 2006, we entered into an exclusive distribution agreement
with Fisher Scientific. There were approximately $265,000 and $42,000 of sales under this agreement in the years ended December 31, 2007 and 2006, respectively.

In February 2008, we entered into a distribution and license agreement with Fisher under which we will provide certain distribution and technology access rights to Fisher. As part of the agreement, Fisher has agreed
to fund a development program related to the development, manufacture and marketing of new molecular diagnostic products on a cost incurred based. Upon commercial launch of the new products, Fisher has agreed to certain minimum purchases over a
six-year period.

Consistent with the requirement under NASDAQ stock market rules, pursuant to its Charter, the Audit Committee of the
Board of Directors is responsible for reviewing and approving in advance all related party transactions as defined under SEC rules and regulations. While we do not have a formal written policy or procedure for the review, approval or ratification of
related party transactions, the audit committee must review the material facts of any such transaction and approve that transaction. The transactions in 2006 with FasTraq and Fisher-Scientific were unanimously approved in advance by the
disinterested members of the Board of Directors.

INDEPENDENCE OF THE BOARD OF DIRECTORS

Our Board of Directors has determined that each of our current directors, except for Mr. Birndorf, our Chairman of the Board and Chief Executive
Officer, and Dr. Dreismann, are independent within the meaning of the applicable independence standards under NASDAQ rules. Dr. Dreismann is not independent because he is the Chief Executive Officer of FasTraq, Inc. and in 2005 and 2006
Nanogen paid FasTraq amounts that exceeded the greater of 5% of the revenue of FasTraq or $200,000. There were no payments made by Nanogen to FasTraq during 2007.



|Item 14. | Principal Accountant Fees and Services
|-------- | --------------------------------------

The following table sets forth the aggregate fees billed to the Company for the annual audits for the fiscal years ended December 31, 2007 and 2006, and all other fees billed to the Company during 2007 and 2006 by its principal
accounting firm, Ernst & Young LLP:



|                   |                |                                 |       |  |   |    
|------------------ | -------------- | ------------------------------- | ----- |  | - | ---
|                   |                | For the YearsEnded December 31,
|                   | 2007           |                                 | 2006 
|                   | (in thousands)
|Audit Fees         |                | $                               | 1,051 |  | $ | 770
|Audit-Related Fees |                |                                 | 211   |  |   | 158
|Tax Fees           |                |                                 |      |  |   | 4  
|All Other Fees     |                |                                 |      |  |   |   
|                   |                |                                 |       |  |   |    
|Total              |                | $                               | 1,262 |  | $ | 932
|                   |                |                                 |       |  |   |    

The Audit Committee has determined that the rendering of all non-audit services by
Ernst & Young, LLP is compatible with maintaining the auditors independence. The fees listed under Audit Fees above were incurred for service related to the annual audit of the Companys consolidated financial
statements, reviews of interim consolidated financial statements and services that are normally provided in connection with statutory and regulatory filings and engagements. In 2007, audit fees also include fees incurred for the audit of the
effectiveness of internal controls over financial reporting as required under the Sarbanes-Oxley regulations. The



29



---

fees listed under Audit-Related Fees above were incurred for service related to accounting consultations and due diligence in connection with
proposed acquisitions. The fees listed under All Other Fees above were incurred for service related to annual license fees for access to an on-line database of accounting and auditing literature. The Audit Committee approves non-audit
services provided by Ernst & Young LLP on an ad hoc basis, and has vested authority with Stelios B. Papadopoulos, the chairman of the Audit Committee, to approve non-audit services as needed.

PART IV



|ITEM 15.Exhibits | and Financial Statement Schedules
|---------------- | ---------------------------------



|(a) | The following documents are filed as part of this Report on Form 10-K/A
|--- | -----------------------------------------------------------------------



| | (3) | Exhibits
| | --- | --------

The following exhibits are referenced or
included in this report:



|        |  |                                                                                                                         
|------- |  | ------------------------------------------------------------------------------------------------------------------------
|Exhibit |  | Description                                                                                                             
|31.3    |  | Certifications of Chief Executive Officer Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended.
|31.4    |  | Certifications of Chief Financial Officer Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended.



30



---

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



|                     |  |               |  |                                                                      
|-------------------- |  | ------------- |  | ---------------------------------------------------------------------
|                     |  | NANOGEN, INC.
|                     |  |              
|Date: April 29, 2008 |  | By:           |  | /S/    HOWARD C.
BIRNDORF                                            
|                     |  |               |  | Howard C. Birndorf Chairman of the Board, and Chief Executive Officer

Pursuant to the requirements to the Securities Exchange Act of 1934, this report has been signed
below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.



|                                                       |  |                                                                                  |  |               
|------------------------------------------------------ |  | -------------------------------------------------------------------------------- |  | --------------
|Signature                                              |  | Title                                                                            |  | Date          
|                                                       |  |                                                                                 
|/s/    HOWARD C.
BIRNDORF Howard C. Birndorf           |  | Chairman of the Board, and Chief Executive Officer (Principal Executive Officer) |  | April 29, 2008
|                                                       |  |                                                                                 
|/S/    NICHOLAS J.
VENUTO Nicholas J. Venuto           |  | Chief Financial Officer (Principal Financial and Accounting Officer)             |  | April 29, 2008
|                                                       |  |                                                                                 
|/S/    DAVID
SCHREIBER David Schreiber                 |  | Director                                                                         |  | April 29, 2008
|                                                       |  |                                                                                 
|/S/    STELIOS B.
PAPADOPOULOS Stelios B. Papadopoulos |  | Director                                                                         |  | April 29, 2008
|                                                       |  |                                                                                 
|/S/    ROBERT E.
WHALEN Robert E. Whalen               |  | Director                                                                         |  | April 29, 2008
|                                                       |  |                                                                                 
|/S/    HEINER
DREISMANN Heiner Dreismann               |  | Director                                                                         |  | April 29, 2008



31